

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

For the Years Ended December 31, 2018 and 2017

Address: No.1, Huanqu 3rd Rd., Kaohsiung Export Processing Zone, Kaohsiung City
Telephone: 886-7-813-9989

Notice to readers

This English-version consolidated financial statement is a summary translation of the Chinese version. If there is any discrepancy between the English and Chinese versions, the Chinese version shall prevail.

Table of Contents

| Item | Page |
|---|--------------|
| 1. Cover | |
| 2. Table of Contents | 1 |
| 3. Representation Letter | 2 |
| 4. Consolidated Balance Sheets | 3-4 |
| 5. Consolidated Statements of Comprehensive Income | 5-6 |
| 6. Consolidated Statements of Changes in Equity | 7 |
| 7. Consolidated Statements of Cash Flows | 8-9 |
| 8. Notes to Consolidated Financial Statements | |
| (1) History and Organization | 10 |
| (2) Date and Procedures of Authorization of Financial Statements | 10 |
| (3) Newly Issued or Revised Standards and Interpretations | 10-16 |
| (4) Summary of Significant Accounting Policies | 16-30 |
| (5) Significant Accounting Judgments and Major Sources of Estimation Uncertainty | 30-31 |
| (6) Details of Significant Accounts | 31-52 |
| (7) Related Party Transactions | 52 |
| (8) Pledged Assets | 52 |
| (9) Significant Contingencies and Unrecognized Contract Commitments | 53 |
| (10) Significant Disaster Loss | 53 |
| (11) Significant Subsequent Events | 53 |
| (12) Others | 53-60 |
| (13) Additional Disclosures | |
| A. Information on Significant Transactions and Investees | 60, 63-67,69 |
| B. Information on Investments in Mainland China | 60,68 |
| (14) Operating Segment Information | 61-62 |

Representation Letter

The entities that are required to be included in the combined financial statements of Taiflex Scientific Company Limited as of and for the year ended December 31, 2018, under the “Criteria Governing the Preparation of Affiliation Reports, Consolidated Business Reports and Consolidated Financial Statements of Affiliated Enterprises” are the same as those included in the consolidated financial statements prepared in conformity with the International Financial Reporting Standards No. 10. In addition, the information required to be disclosed in the combined financial statements is included in the consolidated financial statements. Therefore, Taiflex Scientific Company Limited does not prepare a separate set of combined financial statements.

Very truly yours,

Taiflex Scientific Company Limited

By

Ta-Wen Sun

Chairperson

February 20, 2019

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December 31, 2018 and 2017
(In Thousands of New Taiwan Dollars)

| Assets | Notes | December 31, 2018 | December 31, 2017 |
|---|-------------|----------------------|----------------------|
| Current assets | | | |
| Cash and cash equivalents | 4, 6(1) | \$ 1,862,586 | \$ 1,934,276 |
| Financial assets at fair value through profit or loss - current | 4, 6(2) | 36,438 | 17,463 |
| Notes receivable, net | 4, 6(3) | 1,218,019 | 2,027,778 |
| Accounts receivable, net | 4, 6(4) | 3,678,098 | 2,748,633 |
| Other receivables | | 54,605 | 55,865 |
| Inventories, net | 4, 6(5) | 1,464,307 | 1,626,286 |
| Prepayments | | 85,594 | 95,630 |
| Other current assets | 8 | 25,412 | 26,746 |
| Total current assets | | <u>8,425,059</u> | <u>8,532,677</u> |
| Non-current assets | | | |
| Financial assets at fair value through other comprehensive income - non-current | 4, 6(6) | - | - |
| Financial assets carried at cost - non-current | 4, 6(7) | - | - |
| Investments accounted for under the equity method | 4, 6(8) | 51,470 | - |
| Property, plant and equipment | 4, 6(9) | 3,020,888 | 2,876,458 |
| Intangible assets | 4, 6(10,12) | 114,708 | 121,378 |
| Deferred income tax assets | 4, 6(25) | 157,314 | 130,697 |
| Other non-current assets | 4, 6(11) | 172,451 | 72,026 |
| Total non-current assets | | <u>3,516,831</u> | <u>3,200,559</u> |
| Total assets | | <u>\$ 11,941,890</u> | <u>\$ 11,733,236</u> |

(The accompanying notes are an integral part of the consolidated financial statements.)

(Continued)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS-(Continued)
December 31, 2018 and 2017
(In Thousands of New Taiwan Dollars)

| Liabilities and Equity | Notes | December 31, 2018 | December 31, 2017 |
|---|----------|----------------------|----------------------|
| Current liabilities | | | |
| Short-term loans | 6(13) | \$ 1,362,054 | \$ 656,596 |
| Financial liabilities at fair value through profit or loss - current | 6(14) | 2,656 | 13,351 |
| Contract liabilities – current | 6(20) | 2,372 | - |
| Notes payable | | 65,772 | 324 |
| Accounts payable | | 1,672,749 | 2,416,532 |
| Other payables | | 640,267 | 666,715 |
| Current income tax liabilities | 4, 6(25) | 194,512 | 115,338 |
| Current portion of long-term loans | 6(16) | 12,258 | 44,825 |
| Lease payable - current | 6(15) | 758 | 639 |
| Other current liabilities | | 6,062 | 5,777 |
| Total current liabilities | | <u>3,959,460</u> | <u>3,920,097</u> |
| Non-current liabilities | | | |
| Long-term loans | 6(16) | 329,674 | 210,871 |
| Deferred income tax liabilities | 4, 6(25) | 130,944 | 176,327 |
| Lease payable – non-current | 6(15) | 1,685 | 2,499 |
| Net defined benefit liabilities - non-current | 4, 6(17) | 138,423 | 184,124 |
| Other non-current liabilities | 4, 12 | 255 | 255 |
| Total non-current liabilities | | <u>600,981</u> | <u>574,076</u> |
| Total liabilities | | <u>4,560,441</u> | <u>4,494,173</u> |
| Equity attributable to shareholders of the parent | | | |
| Capital | 6(18) | | |
| Common stock | | 2,091,197 | 2,087,802 |
| Capital collected in advance | | - | 665 |
| Capital surplus | 6(18) | 1,446,639 | 1,441,339 |
| Retained earnings | | | |
| Legal capital reserve | | 815,590 | 742,131 |
| Special capital reserve | | 75,546 | 102,158 |
| Unappropriated earnings | | 2,999,383 | 2,845,730 |
| Total retained earnings | | <u>3,890,519</u> | <u>3,690,019</u> |
| Others | 4 | (166,117) | (92,974) |
| Treasury stocks | 6(18) | - | - |
| Total equity attributable to shareholders of the parent | | <u>7,262,238</u> | <u>7,126,851</u> |
| Non-controlling interests | 4, 6(18) | 119,211 | 112,212 |
| Total equity | | <u>7,381,449</u> | <u>7,239,063</u> |
| Total liabilities and equity | | <u>\$ 11,941,890</u> | <u>\$ 11,733,236</u> |

(Concluded)

(The accompanying notes are an integral part of the consolidated financial statements.)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Years Ended December 31, 2018 and 2017
(In Thousands of New Taiwan Dollars)

| | Notes | 2018 | 2017 |
|--|----------|--------------------|--------------------|
| Net revenue | 4, 6(20) | \$ 9,643,051 | \$ 11,192,892 |
| Cost of revenue | 4, 6(5) | <u>(7,650,007)</u> | <u>(9,058,315)</u> |
| Gross profit | | <u>1,993,044</u> | <u>2,134,577</u> |
| Unrealized sales profit or loss | | - | (95) |
| Gross profit, net | | <u>1,993,044</u> | <u>2,134,482</u> |
| Operating expenses | 4, 6(23) | | |
| Sales and marketing expenses | | (445,484) | (473,619) |
| General and administrative expenses | | (450,461) | (414,505) |
| Research and development expenses | | (264,278) | (257,468) |
| Reversal of expected credit loss | 6(21) | 136,144 | - |
| Total operating expenses | | <u>(1,024,079)</u> | <u>(1,145,592)</u> |
| Operating income | | <u>968,965</u> | <u>988,890</u> |
| Non-operating income and expenses | 6(24) | | |
| Other income | | 40,828 | 27,115 |
| Other gains and losses | | (111,328) | 9,278 |
| Finance costs | | (49,589) | (66,185) |
| Share of profit or loss of associates under the equity method | 4, 6(8) | 19,666 | - |
| Total non-operating income and expenses | | <u>(100,423)</u> | <u>(29,792)</u> |
| Income before income tax | | 868,542 | 959,098 |
| Income tax expense | 4, 6(25) | <u>(189,068)</u> | <u>(212,553)</u> |
| Net income of continuing operations | | <u>679,474</u> | <u>746,545</u> |
| Net income | | <u>679,474</u> | <u>746,545</u> |
| Other comprehensive income (loss) | 6(24) | | |
| Items that will not be reclassified subsequently to profit or loss | | | |
| Remeasurement of defined benefit plan | | 55,488 | 24,130 |
| Income tax related to components of other comprehensive income that will not be reclassified subsequently | | (11,098) | (4,102) |
| Items that may be reclassified subsequently to profit or loss | | | |
| Exchange differences on translation of foreign operations | | (86,077) | (22,115) |
| Income tax related to components of other comprehensive income that may be reclassified subsequently to profit or loss | | 19,368 | 3,760 |
| Total other comprehensive income, net of tax | | <u>(22,319)</u> | <u>1,673</u> |
| Total comprehensive income | | <u>\$ 657,155</u> | <u>\$ 748,218</u> |
| Net income (loss) attributable to: | 4, 6(26) | | |
| Shareholders of the parent | | \$ 672,309 | \$ 734,589 |
| Non-controlling interests | | 7,165 | 11,956 |
| | | <u>\$ 679,474</u> | <u>\$ 746,545</u> |

(The accompanying notes are an integral part of the consolidated financial statements.)

(Continued)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME-(Continued)
For the Years Ended December 31, 2018 and 2017
(In Thousands of New Taiwan Dollars)

| | Notes | 2018 | 2017 |
|--|----------|------------|------------|
| Total comprehensive income (loss) attributable to: | | | |
| Shareholders of the parent | | \$ 650,156 | \$ 736,316 |
| Non-controlling interests | | 6,999 | 11,902 |
| | | \$ 657,155 | \$ 748,218 |
| Earnings per share (NT\$) | 4, 6(26) | | |
| Earnings per share - basic | | \$ 3.22 | \$ 3.55 |
| Earnings per share - diluted | | \$ 3.18 | \$ 3.53 |

(Concluded)

(The accompanying notes are an integral part of the consolidated financial statements.)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
For the Years Ended December 31, 2018 and 2017
(In Thousands of New Taiwan Dollars)

| | Equity Attributable to Shareholders of the Parent | | | | | | | | | | | Total Equity |
|--|---|------------------------------|--------------------|-----------------------|-------------------------|-------------------------|---|---|-----------------|---------------------|---------------------------|---------------------|
| | Retained Earnings | | | | | | Others | | | | | |
| | Common Stock | Capital Collected in Advance | Capital Surplus | Legal Capital Reserve | Special Capital Reserve | Unappropriated Earnings | Exchange Differences on Translation of Foreign Operations | Unrealized Gain/Loss on Financial Assets at Fair Value through Other Comprehensive Income | Treasury Stocks | Total | Non-Controlling Interests | |
| Balance as of January 1, 2017 | \$ 2,083,252 | \$ - | \$1,407,558 | \$ 684,163 | \$ 102,158 | \$ 2,561,335 | \$ (74,673) | \$ - | \$ (98,744) | \$ 6,665,049 | \$ 100,310 | \$ 6,765,359 |
| Appropriation and distribution of 2016 earnings | | | | | | | | | | | | |
| Legal capital reserve | | | | 57,968 | | (57,968) | | | | - | | - |
| Cash dividends for common stocks | | | | | | (412,254) | | | | (412,254) | | (412,254) |
| Changes in other capital surplus | | | | | | | | | | | | |
| Share-based payment | 4,550 | 665 | 33,781 | | | | | | 98,744 | 137,740 | | 137,740 |
| Net income for the year ended December 31, 2017 | | | | | | 734,589 | | | | 734,589 | 11,956 | 746,545 |
| Other comprehensive income (loss) for the year ended December 31, 2017 | | | | | | 20,028 | (18,301) | | | 1,727 | (54) | 1,673 |
| Total comprehensive income | - | - | - | - | - | 754,617 | (18,301) | - | - | 736,316 | 11,902 | 748,218 |
| Balance as of December 31, 2017 | <u>\$ 2,087,802</u> | <u>\$ 665</u> | <u>\$1,441,339</u> | <u>\$ 742,131</u> | <u>\$ 102,158</u> | <u>\$2,845,730</u> | <u>\$ (92,974)</u> | <u>\$ -</u> | <u>\$ -</u> | <u>\$ 7,126,851</u> | <u>\$ 112,212</u> | <u>\$ 7,239,063</u> |
| Balance as of January 1, 2018 | \$ 2,087,802 | \$ 665 | \$1,441,339 | \$ 742,131 | \$ 102,158 | \$2,845,730 | \$ (92,974) | \$ - | \$ - | \$ 7,126,851 | \$ 112,212 | \$ 7,239,063 |
| Effect of retrospective application | | | | | | 6,600 | | (6,600) | | - | | - |
| Adjusted balance as of January 1, 2018 | <u>2,087,802</u> | <u>665</u> | <u>1,441,339</u> | <u>742,131</u> | <u>102,158</u> | <u>2,852,330</u> | <u>(92,974)</u> | <u>(6,600)</u> | <u>-</u> | <u>7,126,851</u> | <u>112,212</u> | <u>7,239,063</u> |
| Appropriation and distribution of 2017 earnings | | | | | | | | | | | | |
| Legal capital reserve | | | | 73,459 | | (73,459) | | | | - | | - |
| Cash dividends for common stocks | | | | | | (522,799) | | | | (522,799) | | (522,799) |
| Changes in other capital surplus | | | | | | | | | | | | |
| Changes in associates accounted for under the equity method | | | (1,553) | | | | | | | (1,553) | | (1,553) |
| Share-based payment | 3,395 | (665) | 6,853 | | | | | | | 9,583 | | 9,583 |
| Reversal of special capital reserve | | | | | (26,612) | 26,612 | | | | - | | - |
| Net income for the year ended December 31, 2018 | | | | | | 672,309 | | | | 672,309 | 7,165 | 679,474 |
| Other comprehensive income (loss) for the year ended December 31, 2018 | | | | | | 44,390 | (66,543) | | | (22,153) | (166) | (22,319) |
| Total comprehensive income | - | - | - | - | - | 716,699 | (66,543) | - | - | 650,156 | 6,999 | 657,155 |
| Balance as of December 31, 2018 | <u>\$ 2,091,197</u> | <u>\$ -</u> | <u>\$1,446,639</u> | <u>\$ 815,590</u> | <u>\$ 75,546</u> | <u>\$2,999,383</u> | <u>\$ (159,517)</u> | <u>\$ (6,600)</u> | <u>\$ -</u> | <u>\$ 7,262,238</u> | <u>\$ 119,211</u> | <u>\$ 7,381,449</u> |

(The accompanying notes are an integral part of the consolidated financial statements.)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Years Ended December 31, 2018 and 2017
(In Thousands of New Taiwan Dollars)

| | 2018 | 2017 |
|--|----------------|----------------|
| Cash flows from operating activities: | | |
| Income before income tax | \$ 868,542 | \$ 959,098 |
| Adjustments: | | |
| Non-cash income and expense items: | | |
| Depreciation | 291,462 | 273,700 |
| Amortization | 28,815 | 27,876 |
| (Reversal of) expected credit loss | (136,144) | 8,967 |
| Net (gain) loss of financial assets (liabilities) at fair value through profit or loss | (7,215) | 41,821 |
| Interest expense | 49,589 | 66,185 |
| Interest income | (20,534) | (17,731) |
| Compensation cost related to share-based payment | - | 22,647 |
| Share of profit of associates under the equity method | (19,666) | - |
| (Gain) loss on disposal of property, plant and equipment | (856) | 418 |
| Gain on liquidation of subsidiaries | (35,761) | - |
| Gain on reversal of impairment loss for non-financial assets | (31,518) | - |
| Others | 79,259 | 40,257 |
| Changes in operating assets and liabilities: | | |
| Increase in financial assets mandatorily at fair value through profit or loss | (22,455) | (9,926) |
| Decrease (increase) in notes receivable | 809,759 | (485,019) |
| (Increase) decrease in accounts receivable | (792,315) | 39,320 |
| Decrease (increase) in other receivables | 2,428 | (9,481) |
| Decrease (increase) in inventories | 82,720 | (534,144) |
| Decrease in prepayments | 10,036 | 5,943 |
| Decrease in other current assets | 1,393 | 542 |
| Increase in other non-current assets | (888) | (4,719) |
| Decrease in contract liabilities | (199) | - |
| Increase (decrease) in notes payable | 65,448 | (177,569) |
| (Decrease) increase in accounts payable | (743,783) | 283,256 |
| (Decrease) increase in other payables | (10,391) | 97,262 |
| Increase (decrease) in other current liabilities | 2,761 | (10,122) |
| Increase in net defined benefit liabilities | 9,787 | 17,978 |
| Increase in other non-current liabilities | - | 209 |
| Cash generated from operations | <u>480,274</u> | <u>636,768</u> |
| Interest received | 19,366 | 18,607 |
| Interest paid | (50,153) | (64,929) |
| Income tax paid | (175,367) | (166,045) |
| Net cash generated by operating activities | <u>274,120</u> | <u>424,401</u> |

(The accompanying notes are an integral part of the consolidated financial statements.)

(Continued)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS-(Continued)
For the Years Ended December 31, 2018 and 2017
(In Thousands of New Taiwan Dollars)

| | 2018 | 2017 |
|---|---------------------|---------------------|
| Cash flows from investing activities: | | |
| Acquisition of property, plant and equipment | \$ (464,333) | \$ (357,753) |
| Disposal of property, plant and equipment | 1,661 | 444 |
| Increase in refundable deposits | - | (389) |
| Decrease in refundable deposits | 7,221 | - |
| Acquisition of intangible assets | (10,448) | (22,546) |
| Increase in other current assets - other financial assets - current | (59) | - |
| Decrease in other current assets - other financial assets - current | - | 16,388 |
| Increase in other non-current assets | (119,009) | - |
| Net cash used in investing activities | <u>(584,967)</u> | <u>(363,856)</u> |
| Cash flows from financing activities: | | |
| Increase in short-term loans | 705,458 | - |
| Decrease in short-term loans | - | (283,187) |
| Increase in long-term loans | 86,236 | - |
| Repayment of long-term loans | - | (515,102) |
| Decrease in lease payable | (1,036) | (341) |
| Distribution of cash dividends | (522,799) | (412,254) |
| Exercise of employee stock options | 9,583 | 18,653 |
| Purchase of treasury stocks by employees | - | 96,440 |
| Net cash generated by (used in) financing activities | <u>277,442</u> | <u>(1,095,791)</u> |
| Effect of exchange rate changes on cash and cash equivalents | <u>(38,285)</u> | <u>(12,686)</u> |
| Net decrease in cash and cash equivalents | (71,690) | (1,047,932) |
| Cash and cash equivalents at beginning of period | 1,934,276 | 2,982,208 |
| Cash and cash equivalents at end of period | <u>\$ 1,862,586</u> | <u>\$ 1,934,276</u> |

(Concluded)

(The accompanying notes are an integral part of the consolidated financial statements.)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2018 and 2017
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

1. History and Organization

Taiflex Scientific Company Limited (“the Company”) was incorporated in August, 1997. Its main operations consist of manufacturing, research and development, and selling of flexible copper-clad laminate, cover layer and PV module backsheet. The shares of the Company commenced trading on Taiwan’s Over-the-Counter Market on December 19, 2003 and were listed on the Taiwan Stock Exchange on December 17, 2009.

2. Date and Procedures of Authorization of Financial Statements

The consolidated financial statements of the Company and its subsidiaries (“the Group”) for the years ended December 31, 2018 and 2017 were approved and authorized for issue in the Board of Directors’ meeting on February 20, 2019.

3. Newly Issued or Revised Standards and Interpretations

(1) The Group has adopted International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC interpretations and SIC interpretations endorsed by the Financial Supervisory Commission (FSC) to take effect for annual periods beginning on January 1, 2018. The first-time adoption does not have any material impact on the Group except for the following descriptions on the nature and the impact of the newly issued or revised standards and interpretations:

A. IFRS 15 “Revenue from Contracts with Customers” (including relevant clarifications associated with IFRS 15 “Revenue from Contracts with Customers”)

IFRS 15 replaces IAS 11 “Construction Contracts”, IAS 18 “Revenue” and relevant interpretations. The Group chooses to recognize the cumulative effect of the first-time adoption on the initial application date (i.e. January 1, 2018) in accordance with the transitional provisions of IFRS 15 and to retrospectively apply IFRS 15 to contracts that are not completed on that date.

The Group’s revenue from contracts with customers mostly involves the sale of goods. The impact of IFRS 15 on the Group’s recognition of revenue is as follows:

- (a) Please refer to Note 4 for accounting policies adopted by the Group after and prior to January 1, 2018.
- (b) Prior to January 1, 2018, the Group recognizes revenue from the sale of goods when the products are delivered to the customers. For reporting periods starting on or after January 1, 2018, revenue is recognized when the promised products are transferred to the customers and the performance obligation is satisfied under IFRS 15. The adoption of IFRS 15 does not have any material impact on the Group’s recognition of revenue from the sale of goods. As for contracts where a part of the considerations is collected upon signing the contracts, the Group assumes the obligations to transfer the goods subsequently. Prior to January 1, 2018, the considerations collected in

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

advance are recognized as other current liabilities. After January 1, 2018, they are recognized as contract liabilities in accordance with IFRS 15. The Group reclassified NT\$2,571 thousand from other current liabilities to contract liabilities on January 1, 2018. In addition, as of December 31, 2018, other current liabilities decreased by NT\$2,372 thousand and contract liabilities increased by NT\$2,372 thousand comparing to the adoption of IAS 18.

(c) Please refer to Notes 4, 5 and 6 for additional disclosures required by IFRS 15.

B. IFRS 9 “Financial Instruments”

IFRS 9 replaces IAS 39. In accordance with the transitional provisions of IFRS 9, the Group chooses not to restate the comparative periods upon the initial application date (i.e. January 1, 2018). The effects of adopting IFRS 9 are as follows:

- (a) The Group adopts IFRS 9 starting from January 1, 2018 and prior to this date, IAS 39 is used. Please refer to Note 4 for details on accounting policies.
- (b) In accordance with the transitional provisions of IFRS 9, the business model is assessed and the financial assets are classified into appropriate categories pursuant to IFRS 9 based on the facts and circumstances that exist as of January 1, 2018. The classifications and carrying amounts of those financial assets as of January 1, 2018 are as follows:

| IAS 39 | | IFRS 9 | |
|---|---------------------|---|---------------------|
| Measurement Category | Carrying Amount | Measurement Category | Carrying Amount |
| Fair value through profit or loss (including carried at cost) | \$ 17,463 | Fair value through profit or loss | \$ 17,463 |
| Measured at amortized cost | | Measured at amortized cost (including cash and cash equivalents, notes and accounts receivables, financial assets measured at amortized cost and other receivables) | |
| Loans and receivables (including cash and cash equivalents, notes and accounts receivables, other financial assets and other receivables) | 6,786,254 | | 6,786,254 |
| Total | \$ 6,803,717 | Total | \$ 6,803,717 |

(c) Detailed information concerning the changes in the classifications of financial assets and financial liabilities for the transition from IAS 39 to IFRS 9 as of January 1, 2018 is as follows:

| IAS 39 | | IFRS 9 | | Adjustment on Retained Earnings | Adjustment on Other Equity |
|---|------------------|---|-----------------|---------------------------------|----------------------------|
| Account | Carrying Amount | Account | Carrying Amount | | |
| Financial assets at fair value through profit or loss | | | | | |
| Designated as at fair value through profit or loss | \$ 17,463 | At fair value through profit or loss | \$ 17,463 | | |
| Available-for-sale financial assets (including financial assets carried at cost) (Note) | 0 | At fair value through other comprehensive income – equity instruments | 0 | \$ 6,600 | (\$ 6,600) |
| Subtotal | \$ 17,463 | | | | |

(Continued)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

| IAS 39 | | IFRS 9 | | Adjustment | Adjustment |
|---|---------------------|--|---------------------|-------------------------|--------------------|
| Account | Carrying Amount | Account | Carrying Amount | on Retained Earnings | on Other Equity |
| Loans and receivables (Note) | | | | | |
| Cash and cash equivalents (excluding cash on hand) | \$ 1,933,624 | Cash and cash equivalents (excluding cash on hand) | \$ 1,933,624 | | |
| Other financial assets | 20,354 | Other financial assets | 20,354 | | |
| Notes receivable | 2,027,778 | Notes receivable | 2,027,778 | | |
| Accounts receivable | 2,748,633 | Accounts receivable | 2,748,633 | | |
| Other receivables | 55,865 | Other receivables | 55,865 | | |
| Subtotal | <u>\$ 6,786,254</u> | | | | |
| Total | <u>\$ 6,803,717</u> | Total | <u>\$ 6,803,717</u> | <u>\$ 6,600</u> | <u>(\$ 6,600)</u> |

(Concluded)

Note: Investments classified as available-for-sale financial assets in accordance with IAS 39 include investments in funds, stocks and bonds of listed (OTC) companies and non-listed (OTC) stocks. Details concerning the changes in classification are as follows:

Investments in stocks (both listed (OTC) and non-listed (OTC) stocks)

The assessment is conducted based on the facts and circumstances that exist as of January 1, 2018. As these investments (equity instruments) are not held-for-trading, the Group chooses to designate them as financial assets at fair value through other comprehensive income. The amount reclassified from available-for-sale financial assets (including ones measured at cost) to financial assets at fair value through other comprehensive income was NT\$0 thousand as of January 1, 2018. Other relevant adjustments are as follows:

Impairment loss is recognized fully for the non-listed (OTC) stocks with an initial carrying amount of NT\$6,600 thousand that are measured at cost pursuant to IAS 39. However, under IFRS 9, those stocks shall be measured at fair value and the recognition of impairment loss is not required. As the fair value is deemed to be NT\$0 thousand as of January 1, 2018, the Group would adjust the carrying amount of financial assets at fair value through other comprehensive income. Retained earnings and other equity (i.e. unrealized gain/loss on financial assets at fair value through other comprehensive income) would also be adjusted by NT\$6,600 thousand each.

For items classified as loans and receivables in accordance with IAS 39, their cash flows are solely payments of principal and interest on the outstanding principal. Based on the facts and circumstances that existed as of January 1, 2018, as the business model is assessed to be one that collects contractual cash flows, they are measured at amortized cost. In addition, no adjustment arisen from the impairment assessment conducted in accordance with IFRS 9 on January 1, 2018. Thus, the carrying amount as of January 1, 2018 is not affected.

(d) Please refer to Notes 4, 5, 6 and 12 for disclosures required by IFRS 7 and IFRS 9.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

C. Disclosure Initiative (Amendments to IAS 7 “Statement of Cash Flows”)

A reconciliation between the opening and closing balances for liabilities arising from financing activities of the Group is provided. Please refer to Note 12 for disclosures required.

- (2) The Group has not adopted the following new, revised and amended standards or interpretations issued by International Accounting Standards Board (IASB) and endorsed by FSC:

| No. | Projects of New, Revised and Amended Standards or Interpretations | Effective Date |
|--|---|-----------------|
| IFRS 16 | Leases | January 1, 2019 |
| IFRIC 23 | Uncertainty over Income Tax Treatments | January 1, 2019 |
| IAS 28 | Investments in Associates and Joint Ventures | January 1, 2019 |
| IFRS 9 | Prepayment Features with Negative Compensation | January 1, 2019 |
| Improvements to IFRS (2015-2017 cycle) | | January 1, 2019 |
| IAS 19 | Plan Amendment, Curtailment or Settlement | January 1, 2019 |

A. IFRS 16 “Leases”

The new standard requires lessees to adopt a single accounting model for all leases except for short-term leases or leases of low value assets, i.e. to recognize right-of-use assets and lease liabilities on the balance sheets, and lease-related depreciation and interest expense on the statements of comprehensive income. Moreover, lessors continue to classify leases as operating or finance leases. However, more extensive disclosure is required.

B. IFRIC 23 “Uncertainty over Income Tax Treatments”

The interpretation clarifies the application of recognition and measurement requirements under IAS 12 “Income Taxes” when there is uncertainty over income tax treatments.

C. Amendments to IAS 28 “Investments in Associates and Joint Ventures”

The amendments clarify that prior to the adoption of IAS 28, IFRS 9 shall be used to account for the long-term interests that form part of the net investment in the associates or joint ventures. Also, during the application of IFRS 9, adjustments arising from the adoption of IAS 28 shall not be considered.

D. Prepayment Features with Negative Compensation (Amendments to IFRS 9)

The amendments allow financial assets with prepayment features (parties to the contract may pay or receive reasonable compensation for early termination of the contracts) to be measured at amortized cost or at fair value through other comprehensive income.

E. Improvements to IFRS (2015-2017 cycle)

IFRS 3 “Business Combinations”

The amendments clarify that when an entity having joint control over a joint operation

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

obtains control of the joint operation, it shall remeasure previously held interests in that business.

IFRS 11 “Joint Arrangements”

The amendments clarify that when an entity that participates in (but has no joint control over) a joint operation obtains joint control over the joint operation, it shall not remeasure previously held interests in that business.

IAS 12 “Income Taxes”

The amendments clarify that entities shall recognize income tax consequences of dividends in profit or loss, other comprehensive income or equity, depending on how the originating transaction or event that has given rise to the dividends is recognized.

IAS 23 “Borrowing Costs”

The amendments clarify that when an asset is ready for its intended use or sale, the entity shall treat borrowings related specifically to the acquisition of such an asset as general borrowings.

F. Plan Amendment, Curtailment or Settlement (Amendments to IAS 19)

The amendments clarify that when changes occurred to the defined benefit plan (e.g. amendment, curtailment or settlement), entities shall remeasure the net defined benefit liability or asset using the updated assumptions.

The abovementioned new, revised and amended standards or interpretations are issued by IASB and endorsed by FSC to take effect from January 1, 2019. Except for A with effects listed below, the adoption of these new, revised and amended standards and interpretations will not have a significant effect on the Group.

A. IFRS 16 “Leases”

IFRS 16 “Leases” replaces IAS 17 “Leases”, IFRIC 4 “Determining Whether an Arrangement Contains a Lease”, SIC 15 “Operating Leases – Incentives” and SIC 27 “Evaluating the Substance of Transactions in the Legal Form of a Lease”. The effect of IFRS 16 on the Group is as follows:

- (a) For definition of leases, the Group adopts the transitional provisions of IFRS 16 and elects not to reevaluate whether contracts are (or contain) leases on the initial application date (i.e. January 1, 2019). Contracts previously identified as leases under IAS 17 and IFRS 4 are now subject to IFRS 16. For contracts previously identified as not containing leases under IAS 17 and IFRS 4, IFRS 16 does not apply.

As a lessee, the Group elects not to restate the comparative information in accordance with the transitional provisions of IFRS 16 and recognizes cumulative effect of initial application as an adjustment to the opening balance of retained earnings (or other component of equity, if appropriate) on January 1, 2019.

- i. Leases classified as operating leases

The Group plans to measure leases classified as operating leases under IAS 17 by the present value of remaining lease payments (discounted using the incremental borrowing rate of lessee as of January 1, 2019) and recognize lease

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
 (In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

liabilities on January 1, 2019. In addition, the right-of-use assets are measured and recognized on a lease-by-lease basis using one of the following amounts:

- (i) the carrying amount of the right-of-use assets as if IFRS 16 has applied since the beginning of leases. However, the amount shall be discounted by the incremental borrowing rate of lessee as of January 1, 2019, or
- (ii) the amount of lease liabilities, adjusted for all prepaid or accrued lease payments associated with the leases (recognized in the balance sheet immediately before January 1, 2019).

The Group's right-of-use assets and lease liabilities are expected to increase by NT\$271,336 thousand and NT\$271,336 thousand, respectively, on January 1, 2019.

ii. Leases classified as finance leases

For leases classified as finance leases under IAS 17, the Group plans to reclassify lease assets of NT\$2,245 thousand and lease payable of NT\$2,443 thousand recognized previously under IAS 17 to right-of-use assets of NT\$2,245 thousand and lease liabilities of NT\$2,443 thousand, respectively.

- (b) The Group provides additional disclosures in accordance with the lessee and lessor provisions of IFRS 16.

- (3) As of the date of issuance of the financial statements, the Group has not adopted the following new, revised and amended standards or interpretations issued by IASB and but not yet endorsed by FSC:

| No. | Projects of New, Revised and Amended Standards or Interpretations | Effective Date |
|--------------------|---|--------------------------|
| IFRS 10 and IAS 28 | Sale or Contribution of Assets between an Investor and its Associate or Joint Venture | To be determined by IASB |
| IFRS 17 | Insurance Contracts | January 1, 2021 |
| IFRS 3 | Definition of a Business | January 1, 2020 |
| IAS 1 and IAS 8 | Definition of Material | January 1, 2020 |

The potential effects of adopting above standards or interpretations, which are issued by IASB but not yet endorsed by FSC, in the preparation of Group's financial statements for future periods are listed below:

- A. Amendments to IFRS 10 "Consolidated Financial Statements" and IAS 28 "Investments in Associates and Joint Ventures" - Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

The plan deals with the inconsistency between IFRS 10 "Consolidated Financial Statements" and IAS 28 "Investments in Associates and Joint Ventures" in relation to the loss of control of a subsidiary that is contributed to an associate or a joint venture. IAS 28 states that when non-monetary assets are contributed in exchange for an interest in an associate or a joint venture, the share of gains or losses shall be eliminated in accordance with the treatments of a downstream transaction. However, IFRS 10 requires a full recognition of gains or losses arising from the loss of control of a subsidiary. The amendments place restrictions on the above-mentioned rules of IAS 28 so that gains or

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

losses shall be recognized in full for sale or contribution of assets that constitute a business as defined in IFRS 3.

The amendments also change IFRS 10 so that gains or losses arising from the sale or contributions of a subsidiary, that does not constitute a business as defined in IFRS 3, between an investor and its associate or joint venture are recognized only to the extent of their shares owned by non-investors.

B. Definition of a Business (Amendments to IFRS 3)

The amendments clarify the definition of a business under IFRS 3 “Business Combinations”, assisting enterprises in identifying whether a transaction shall be accounted for as a business combination or acquisition of assets. IFRS 3 continues to adopt market participants’ perspective in determining whether the activities or assets acquired are considered a business. Actions taken include clarifying the minimum requirements of a business, adding guidance to help enterprises assessing whether the acquisition process is substantive, and narrowing the definitions of a business and outputs.

C. Definition of Material (Amendments to IAS 1 and IAS 8)

Information is considered material if it can be reasonably expected that the omission, misstatement or obscurity of such information would have effect on decisions made by primary users of general-purpose financial statements based on those financial statements. The amendments clarify that materiality depends on the nature or magnitude of information. Enterprises shall determine whether the information, either individually or combined with other information, is material in the financial statements. If information can be reasonably expected to have effect on primary users, the misstatement of such information is considered material.

The Group currently assesses the potential effects of the new, revised and amended standards or interpretations in the preceding paragraphs on the financial status and performance of the Group. The outcome will be disclosed upon completion of the assessment.

4. Summary of Significant Accounting Policies

(1) Statement of compliance

The consolidated financial statements for the years ended December 31, 2018 and 2017 have been prepared in conformity with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IFRSs, IASs, IFRIC interpretations and SIC interpretations endorsed and issued into effect by FSC.

(2) Basis of preparation

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments that have been measured at fair value.

(3) Basis of consolidation

Preparation principle of consolidated financial statements

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if and only if it has:

- A. power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

- B. exposure, or rights, to variable returns from its involvement with the investee, and
- C. the ability to use its power over the investee to affect its returns

When the Group directly or indirectly has less than a majority of the voting or similar rights over an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- A. the contractual arrangement with the other vote holders of the investee
- B. rights arising from other contractual arrangements
- C. the voting rights and potential voting rights

The Group reassesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three control elements.

Subsidiaries are fully consolidated from the acquisition date, being the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases. The financial statements of the subsidiaries are adjusted to be in line with the accounting policies used by the Group. All intra-group balances, transactions, unrealized gains and losses resulting from intra-group transactions and dividends are eliminated in full.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. Total comprehensive income of the subsidiaries is attributed to the owners of the parent and to the non-controlling interests (NCIs) even if this results in a deficit balance of the NCIs.

If the Group loses control of a subsidiary, it:

- A. derecognizes the assets (including goodwill) and liabilities of the subsidiary;
- B. derecognizes the carrying amount of any NCI;
- C. recognizes the fair value of the consideration received;
- D. recognizes the fair value of any investment retained;
- E. recognizes any surplus or deficit in profit or loss for the period; and
- F. reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss.

The consolidated entities are listed as follows:

| Investor | Subsidiary | Main Business | Percentage of Ownership | |
|-------------|--|--|-------------------------|------------|
| | | | 2018.12.31 | 2017.12.31 |
| The Company | Taistar Co., Ltd. (Taistar) | Investment holding | 100.00% | 100.00% |
| The Company | Leadmax Ltd. (Leadmax) | Trading of electronic materials | 100.00% | 100.00% |
| The Company | Koatech Technology Corporation (Koatech) | Manufacturing and selling of electronic materials and components | 53.86% | 53.86% |
| The Company | TFS Co., Ltd. (TFS) | Investment holding | 100.00% | 100.00% |

(Continued)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

| Investor | Subsidiary | Main Business | Percentage of Ownership | |
|-------------|--|--|-------------------------|------------|
| | | | 2018.12.31 | 2017.12.31 |
| The Company | Taiflex Scientific Japan Co., Ltd. (Japan Taiflex) | Trading and technical support of electronic materials | 100.00% | 100.00% |
| The Company | Taiflex USA Corporation (USA Taiflex) | Technical support and marketing of electronic materials | 100.00% | - |
| The Company | Richstar Co., Ltd. (Richstar) | Investment holding | 53.01% | - |
| Taistar | TSC International Ltd. (TSC) | Investment holding | 100.00% | 100.00% |
| TSC | Kunshan Taiflex Electronic Material Co., Ltd. (Kunshan Taiflex) | Trading of coating materials for high polymer film and copper foil | - (Note) | 100.00% |
| TSC | Taiflex Scientific (Kunshan) Co., Ltd. (Taiflex Kunshan) | Manufacturing and selling of coating materials for high polymer film and copper foil | 100.00% | 100.00% |
| TFS | Richstar Co., Ltd. (Richstar) | Investment holding | 46.99% | 100.00% |
| Richstar | Shenzhen Taiflex Electronic Co., Ltd. (Shenzhen Taiflex) | Trading of coating materials for high polymer film and copper foil | 100.00% | 100.00% |
| Richstar | Rudong Fuzhan Scientific Co., Ltd. (Rudong Fuzhan) | Manufacturing and selling of electronic materials | 100.00% | - |
| Koatech | KTC Global Co., Ltd. (KTC Global) | Investment holding | 100.00% | 100.00% |
| KTC Global | KTC PanAsia Co., Ltd. (KTC PanAsia) | Investment holding | 100.00% | 100.00% |
| KTC PanAsia | Kunshan Koatech Technology Corporation (Kunshan Koatech) | A wholesaler and a commission agent of electronic materials and components | 100.00% | 100.00% |

(Concluded)

Note: The liquidation of Kunshan Taiflex Electronic Material Co., Ltd. was completed by August, 2018.

(4) Foreign currency transactions and translation of financial statements in foreign currencies

The Group's consolidated financial statements are presented in New Taiwan Dollars, which is the Company's functional currency. Each entity in the Group determines its own functional currency and items in the financial statements of each entity are measured using that functional currency.

Transactions in foreign currencies are initially recognized by each entity of the Group at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the closing rates of that date; non-monetary items measured at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value is measured; and non-monetary items measured at historical cost that are denominated in foreign currencies are retranslated using the exchange rates as at the dates of the initial transactions.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

All exchange differences arising on the settlement or translation of monetary items are recognized in profit or loss in the period in which they arise, except for the following:

- A. Exchange differences arising from foreign currency borrowings for an acquisition of a qualifying asset to the extent that they are regarded as an adjustment to interest costs are included in the borrowing costs that are eligible for capitalization.
- B. Foreign currency items within the scope of IFRS 9 “Financial Instruments” (prior to January 1, 2018: IAS 39) are accounted for based on the accounting policies for financial instruments.
- C. Exchange differences arising on a monetary item that forms part of a reporting entity’s net investment in a foreign operation are recognized initially in other comprehensive income and reclassified from equity to profit or loss upon disposal of the net investment.

When a gain or loss on a non-monetary item is recognized in other comprehensive income, any exchange component of that gain or loss is recognized in other comprehensive income. When a gain or loss on a non-monetary item is recognized in profit or loss, any exchange component of that gain or loss is recognized in profit or loss.

In the preparation of consolidated financial statements, the assets and liabilities of foreign operations are translated into New Taiwan Dollars using the closing rates at the reporting date and income and expense items are translated at the average exchange rates for the period. The exchange differences arising on the translation are recognized in other comprehensive income. Upon disposal of the foreign operations, the cumulative exchange differences recognized in other comprehensive income and accumulated in the separate component of equity are reclassified from equity to profit or loss when recognizing the gain or loss on disposal. The partial disposal involving the loss of control of a subsidiary that includes a foreign operation, and the partial disposal of interests in an associate or a joint arrangement that includes a foreign operation while the retained interests are financial assets that include a foreign operation are accounted for as disposals.

On the partial disposal of a subsidiary that includes a foreign operation while retaining control, the proportionate share of the cumulative amount of the exchange differences recognized in other comprehensive income is re-attributed to the NCIs in that foreign operation instead of being recognized in profit or loss. In partial disposal of an associate or a joint arrangement that includes a foreign operation while retaining significant influence or joint control, the proportionate share of the cumulative amount of the exchange differences is reclassified to profit or loss.

Goodwill arising from the acquisition of a foreign operation and fair value adjustments on the carrying amounts of assets and liabilities of such an acquisition are deemed as assets and liabilities of the foreign operation and expressed in the functional currency of the foreign operation.

(5) Classification of current and non-current assets and liabilities

An asset is classified as current when:

- A. the Group expects to realize the asset, or intends to sell or consume it, in its normal operating cycle
- B. the Group holds the asset primarily for the purpose of trading
- C. the Group expects to realize the asset within twelve months after the reporting period

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

- D. the asset is cash or cash equivalent, unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is classified as current when:

- A. the Group expects to settle the liability in its normal operating cycle
B. the Group holds the liability primarily for the purpose of trading
C. the liability is due to be settled within twelve months after the reporting period
D. the Group does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

All other liabilities are classified as non-current.

(6) Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, demand deposits and short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value (including time deposits with terms equal to or less than twelve months).

(7) Financial instruments

Financial assets and financial liabilities are recognized when the Group becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities within the scope of IFRS 9 “Financial Instruments” (prior to January 1, 2018: IAS 39) are recognized initially at fair value plus or minus, in the case of financial assets and financial liabilities not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issuance of the financial assets or financial liabilities.

A. Recognition and measurement of financial assets

The accounting treatment starting from January 1, 2018 is as follows:

The Group accounts for regular way purchase or sales of financial assets on the trade date basis.

The Group classifies financial assets as subsequently measured at amortized cost, at fair value through other comprehensive income or at fair value through profit or loss based on the following two conditions:

- (a) the business model for managing the financial assets, and
(b) the contractual cash flow characteristics of the financial assets

Financial assets measured at amortized cost

A financial asset satisfying both conditions below is measured at amortized cost and presented as notes receivables, accounts receivables, financial assets measured at amortized cost and other receivables on the balance sheet:

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

- (a) the business model for managing the financial assets: the financial asset is held to collect its contractual cash flows, and
- (b) the contractual cash flow characteristics of the financial assets: cash flows are solely payments of principal and interest on the outstanding principal.

Such financial assets (excluding ones involved in a hedging relationship) are subsequently measured at amortized cost {the amount initially recognized less principal repayments, plus or minus the cumulative amortization of the difference between the initial amount and the maturity amount (calculated using the effective interest method), and adjusted for loss allowance}. A gain or loss is recognized in profit or loss when the financial asset is derecognized, going through the amortization process or recognizing the impairment gains or losses.

Interest calculated by the effective interest method (applying the effective interest rate to the gross carrying amount of financial assets) or under one of the follow situations is recognized in profit or loss:

- (a) For purchased or originated credit-impaired financial assets, interest is calculated by applying the credit-adjusted effective interest rate to the amortized cost of the financial assets.
- (b) For financial assets that do not belong to the former category but subsequently have become credit-impaired, interest is calculated by applying the effective interest rate to the amortized cost of the financial assets.

Financial assets at fair value through other comprehensive income

A financial asset satisfying both conditions below is measured at fair value through other comprehensive income and presented as financial assets at fair value through other comprehensive income on the balance sheet:

- (a) the business model for managing the financial assets: the financial asset is held to collect its contractual cash flows and for sale, and
- (b) the contractual cash flow characteristics of the financial assets: cash flows are solely payments of principal and interest on the outstanding principal.

Recognition of gain or loss on such a financial asset is described below:

- (a) Prior to its derecognition or reclassification, the gain or loss on a financial asset at fair value through other comprehensive income is recognized in other comprehensive income, except for impairment gains or losses and foreign exchange gains or losses, which are recognized in profit or loss.
- (b) Upon derecognition, the cumulative gain or loss previously recognized in other comprehensive income is reclassified from equity to profit or loss as a reclassification adjustment.
- (c) Interest calculated by the effective interest method (applying the effective interest rate to the gross carrying amount of financial assets) or under one of the follow situations is recognized in profit or loss:
 - i. For purchased or originated credit-impaired financial assets, interest is calculated by applying the credit-adjusted effective interest rate to the

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

amortized cost of the financial assets.

- ii. For financial assets that do not belong to the former category but subsequently have become credit-impaired, interest is calculated by applying the effective interest rate to the amortized cost of the financial assets.

In addition, for an equity instrument within the scope of IFRS 9 that is not held for trading and the contingent consideration recognized by an acquirer in a business combination under IFRS 3 does not apply, the Group makes an (irrevocable) election at initial recognition to present its subsequent changes in the fair value in other comprehensive income. Amounts presented in other comprehensive income cannot be subsequently transferred to profit or loss (upon disposal of such equity instrument, its cumulative amount in other equity is transferred directly to retained earnings) and shall be recognized as a financial asset measured at fair value through other comprehensive income on the balance sheet. Dividends from the investment are recognized in profit or loss unless they clearly represent the recovery of a part of the investment cost.

Financial assets at fair value through profit or loss

Except for financial assets that are measured at amortized cost or at fair value through other comprehensive income due to the satisfaction of certain conditions, all other financial assets are measured at fair value through profit or loss and presented as financial assets at fair value through profit or loss on the balance sheet.

Those financial assets are measured at fair value and the gains or losses resulting from their remeasurement are recognized in profit or loss, which include dividends or interests received on such financial assets.

B. Impairment of financial assets

The accounting treatment from January 1, 2018 is as follows:

The Group recognizes and measures the loss allowance for debt instrument investments at fair value through other comprehensive income and financial assets measured at amortized cost at an amount equal to expected credit losses. The loss allowance on debt instrument investments at fair value through other comprehensive income is recognized in other comprehensive income and does not reduce the carrying amount of the investments.

The Group measures expected credit loss in a way that reflects:

- (a) an unbiased and probability-weighted amount that is determined by evaluating a range of possible outcomes;
- (b) the time value of money; and
- (c) reasonable and supportable information about past events, current conditions and forecasts of future economic conditions that is available (without undue cost or effort at the balance sheet date)

The loss allowance is measured as follows:

- (a) at an amount equal to 12-month expected credit losses: including financial assets whose credit risk has not increased significantly since initial recognition or ones that are determined to have low credit risk at the balance sheet date. In addition, financial

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

assets whose loss allowance is measured at an amount equal to lifetime expected credit losses in the previous reporting period, but the condition of a significant increase in credit risk since initial recognition is no longer met at the current balance sheet date shall also be included.

- (b) at an amount equal to lifetime expected credit losses: including financial assets whose credit risk has increased significantly since initial recognition or purchased or originated credit-impaired financial assets.
- (c) for accounts receivables or contract assets arising from transactions within the scope of IFRS 15, the Group measures the loss allowance at an amount equal to lifetime expected credit losses.

At each reporting date, the Group assesses whether the credit risk on a financial asset has increased significantly since initial recognition by comparing the risk of a default at the reporting date and initial recognition. Please refer to Note 12 for further details on credit risk.

(8) Derivative financial instrument

The Group uses derivative instruments to hedge its foreign currency risks and interest rate risks. A derivative is classified in the balance sheet as financial assets or liabilities at fair value through profit or loss (held for trading) except for derivatives that are designated effective hedging instruments which are classified as derivative assets or liabilities for hedging.

Derivative instruments are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Any gains or losses arising from changes in the fair value of derivatives are taken directly to profit or loss, except for the effective portion of cash flow hedges and hedges of a net investment in a foreign operation, which is recognized in equity.

Prior to January 1, 2018, derivatives embedded in host contracts are accounted for as separate derivatives if their economic characteristics and risks are not closely related to those of the host contracts and the host contracts are not held for trading or designated as at fair value through profit or loss.

(9) Inventories

Inventories are valued at the lower of cost or net realizable value item by item.

Costs incurred in bringing each inventory to its present location and condition are accounted for as follows:

| | |
|-------------------------------------|--|
| Raw materials | - Actual purchase cost |
| Work in progress and finished goods | - Cost of direct materials and labor and a proportion of manufacturing overheads based on normal operating capacity. Borrowing costs are excluded. |

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and costs necessary to make the sale.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(10) Investments accounted for under the equity method

An associate is an entity over which the Group has significant influence. The Group's investment in its associate is accounted for under the equity method other than those that meet the criteria to be classified as assets held for sale.

Under the equity method, the investment in the associate is carried in the balance sheet at cost and adjusted thereafter for the post-acquisition change in the Group's share of net assets of the associate. After the interest in the associate is reduced to zero, additional losses are provided for, and a liability is recognized, only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate. Unrealized gains and losses resulting from transactions between the Group and the associate are eliminated to the extent of the Group's related interest in the associate.

The financial statements of the associate are prepared for the same reporting period as the Group.

The Group determines at each reporting date whether there is any objective evidence indicating that its investment in the associate is impaired. If this is the case, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate and its carrying value and recognizes the amount in the "share of profit or loss of associates under the equity method" in the statements of comprehensive income.

Upon loss of significant influence over the associate, the Group measures and recognizes any retaining investment at its fair value. Any difference between the carrying amount of the associate upon loss of significant influence and the fair value of the retaining investment plus proceeds from disposal is recognized in profit or loss.

(11) Property, plant and equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment, if any. Such cost includes the cost of dismantling and removing the item and restoring the site on which it is located and borrowing costs for construction in progress if the recognition criteria are met. Each part of property, plant and equipment with a cost that is significant in relation to the total cost is depreciated separately. When significant parts of property, plant and equipment are required to be replaced in intervals, the Group recognizes such parts separately as individual assets with specific useful lives and depreciation methods. The carrying amount of those parts is derecognized in accordance with the provisions of IAS 16 "Property, Plant and Equipment." When a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement cost if the recognition criteria are satisfied. All other repair and maintenance costs are recognized in profit or loss as incurred.

Depreciation is calculated on a straight-line basis over the estimated economic lives of the following assets:

| | |
|-------------------------|----------------|
| Buildings | 20 to 50 years |
| Machinery and equipment | 10 years |
| Hydropower equipment | 5 to 20 years |
| Testing equipment | 10 years |
| Miscellaneous equipment | 5 to 10 years |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

An item of property, plant and equipment or any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset is recognized in profit or loss.

The residual values, useful lives and depreciation methods of property, plant and equipment are reviewed at the end of each financial year. If the expected values differ from the estimates, the differences are recorded as a change in accounting estimate.

(12) Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial time period to get ready for its intended use or sale are capitalized as part of the cost of the respective assets. All other borrowing costs are expensed in the period they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

(13) Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is its fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Internally generated intangible assets, which fail to meet the recognition criteria, are not capitalized. They are recognized in profit or loss as incurred.

The useful lives of intangible assets are categorized as either finite or indefinite.

Intangible assets with finite lives are amortized on a straight-line basis over the useful economic lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at the end of each financial year. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization method or period, as appropriate, and are treated as changes in accounting estimates.

Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually, either individually or at the cash-generating unit (CGU) level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

Gains or losses arising from derecognition of an intangible asset are recognized in profit or loss.

In-process intangible assets - research and development costs

Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset when the Group can demonstrate:

- A. the technical feasibility of completing the intangible asset so that it will be available for use or sale
- B. its intention to complete and its ability to use or sell the asset
- C. how the asset will generate future economic benefits

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

- D. the availability of resources to complete the asset
- E. the ability to measure reliably the expenditure during development

Following initial recognition of the development expenditure as an asset, the cost model is applied, i.e. the asset is required to be carried at cost less any accumulated amortization and accumulated impairment losses. During the period of development, the asset is tested for impairment annually. Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit.

(14) Impairment of non-financial assets

The Group assesses whether there is any indication that an asset in the scope of IAS 36 “Impairment of Assets” may be impaired at the end of each reporting period. If any such indication exists, or when annual impairment testing for an asset is required, the Group would conduct impairment tests at individual or CGU level. Where the carrying amount of an asset or its CGU exceeds its recoverable amount, the asset is considered impaired. An asset’s recoverable amount is the higher of an asset’s net fair value or its value in use.

For assets excluding goodwill, an assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the Group estimates the recoverable amount of the asset or CGU. A previously recognized impairment loss is reversed only if there has been a change in the estimated service potential of an asset which in turn increases the recoverable amount. However, the reversal is limited so that the carrying amount of the asset does not exceed the carrying amount that would have been determined, net of depreciation or amortization, had no impairment loss been recognized for the asset in prior years.

A CGU, or groups of CGUs, to which goodwill has been allocated is tested for impairment annually at the same time, irrespective of whether there is any indication of impairment. If an impairment loss is to be recognized, it is first allocated to reduce the carrying amount of any goodwill allocated to the CGU (or group of units), then to the other assets of the unit (or group of units) pro rata based on the carrying amount of each asset in the unit (or group of units.) Impairment losses relating to goodwill cannot be reversed in future periods for any reason.

Impairment loss or reversals of continuing operations are recognized in profit or loss.

(15) Provisions

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, of which amount can be reliably estimated. Where the Group expects some or all of a provision to be reimbursed, the reimbursement is recognized as a separate asset only when it is virtually certain. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects the risks specific to the liability. Where discounting is used, the increase in the liability due to the passage of time is recognized as a borrowing cost.

(16) Treasury stocks

The Group recognizes the parent company’s stocks acquired (treasury stocks) at cost and as a deduction to equity. Difference between the carrying amount and the consideration is recognized in equity.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(17) Revenue recognition

The accounting treatment from January 1, 2018 is as follows:

The Group's revenue from contracts with customers mostly involves the sale of goods. The accounting treatment is detailed as follows:

The Group manufactures and sells goods. Revenues are recognized when goods have been delivered to the customers and customers have obtained control (i.e. the customers can direct the use of goods and obtain substantially all remaining benefits from the goods). The main products of the Group are flexible copper-clad laminate, cover layer and PV module backsheet. Revenues are recognized based on the prices stated on the contracts.

The credit terms of accounts receivable are set at 60 to 150 days. Accounts receivables are recognized when the control over goods is transferred and the Group has an unconditional right to collect the considerations. Those accounts receivables usually have a short collection period and do not have a significant financing component.

As for contracts where a part of the considerations is collected upon signing the contracts, the Group assumes the obligations to transfer the goods subsequently. Thus, they are recognized as contract liabilities. As it usually takes less than one year for the said contract liabilities to be reclassified to revenue, no significant financing component has arisen.

(18) Post-employment benefit plans

All regular employees of the Company are entitled to a pension plan that is managed by an independently administered pension fund committee. Fund assets are deposited under the committee's name in the specific bank account and hence, not associated with the Company. Therefore, fund assets are not included in the consolidated financial statements.

For the defined contribution plan, the Company would make a monthly contribution of no less than 6% of the monthly wages of the employees subject to the plan. The Company recognizes expenses for the defined contribution plan in the period in which the contribution becomes due.

Post-employment benefit plan that is classified as a defined benefit plan uses the Projected Unit Credit Method to measure its obligations and costs based on actuarial assumptions. The remeasurements of net defined benefit liability (asset) include return on plan assets and any changes in the effect of the asset ceiling, and exclude amounts included in the net interest on the net defined benefit liability (asset) and actuarial gains and losses. The remeasurements of net defined benefit liability (asset) are recognized in other comprehensive income in the periods they occur and immediately recognized in the retained earnings. Past service cost is the change in the present value of defined benefit obligation due to plan amendments or curtailments. It is recognized as an expense at the earlier of the following two dates:

- A. when a plan amendment or curtailment occurs; and
- B. the date when the Group recognizes any related restructuring costs or termination benefits.

Net interest on the net defined benefit liability (asset) is determined by multiplying the net defined benefit liability (asset) by the discount rate. Both net defined benefit liability (asset) and discount rate are determined at the beginning of annual reporting period. Changes in net defined benefit liability (asset) due to actual contributions and benefits paid during the period shall be taken into consideration.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(19) Share-based payment transactions

The cost of equity-settled transactions between the Group and its employees is recognized based on the fair value of the equity instruments on the grant date. The fair value of the equity instruments is determined by using an appropriate pricing model.

The cost of equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the service conditions and performance are fulfilled. The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The movement in cumulative cost recognized for share-based payment transactions as at the beginning and end of that period is recognized as profit or loss for the period.

No expense is recognized for awards that do not ultimately vest, except for equity-settled transactions where vesting is conditional upon a market or non-vesting condition, which are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other service or performance conditions are satisfied.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

(20) Income tax

Income tax expense (benefit) is the aggregate amount included in the determination of profit or loss for the period in respect of current income tax and deferred income tax.

Current income tax

Current income tax liabilities (assets) for the current and prior periods are measured based on the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. Current income tax relating to items recognized in other comprehensive income or directly in equity is recognized in other comprehensive income or equity respectively, instead of in profit or loss.

The additional income tax for undistributed earnings is recognized as income tax expense in the year when the distribution proposal is approved in the shareholders' meeting.

Deferred income tax

Deferred income tax is the temporary difference between the tax bases of assets and liabilities and their carrying amounts in balance sheet at the reporting date.

Deferred income tax liabilities are recognized for all taxable temporary differences, except:

- A. Where the taxable temporary differences arise from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit (loss);
- B. Where the taxable temporary differences are associated with investments in subsidiaries and associates and the timing of its reversal can be controlled; and it is probable that the temporary differences will not be reversed in the foreseeable future.

Deferred income tax assets are recognized for all deductible temporary differences, any unused tax losses and carryforward of unused tax credits to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses can be utilized, except:

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

- A. Where the deferred income tax asset is related to the deductible temporary difference arising from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- B. Where the deferred income tax asset is related to the deductible temporary differences associated with investments in subsidiaries and associates. The deferred income tax asset is recognized only to the extent that it is probable that the temporary differences will be reversed in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the reporting date. The measurement of deferred income tax assets and liabilities reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. Deferred income tax relating to items recognized outside profit or loss cannot be recognized as profit or loss. Instead, it is recognized in correlation to the underlying transaction either in other comprehensive income or directly in equity. Deferred income tax assets are reassessed and recognized at each reporting date.

Deferred income tax assets and liabilities are offset only if a legally enforceable right exists to set off current income tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority.

(21) Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The consideration transferred, the identifiable assets acquired and liabilities assumed are measured at fair value as at the acquisition date. For each business combination, the acquirer measures any NCI in the acquiree either at fair value or at the NCI's proportionate share of the acquiree's identifiable net assets. Acquisition-related costs are accounted for as expenses in the periods in which the costs are incurred and are classified under general and administrative expenses.

When the Group acquires a business, it assesses the assets acquired and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in acquiree's host contracts.

If the business combination is achieved in stages, the acquirer's previously held equity interest in the acquiree is remeasured at fair value at the acquisition date and the resulting gain or loss is recognized in profit or loss.

Any contingent consideration to be transferred by the acquirer will be recognized at the acquisition-date fair value. Subsequent changes to the fair value of the contingent consideration which is deemed to be an asset or liability will be recognized in accordance with IFRS 9 (prior to January 1, 2018: IAS 39) as a change in either the profit or loss or other comprehensive income. However, if the contingent consideration is classified as equity, it should not be remeasured until it is finally settled within equity.

Goodwill is initially measured as the excess amount of the aggregate of the consideration transferred and the NCI over the net fair value of the identifiable assets acquired and the liabilities assumed. If this aggregate is lower than the fair value of the net assets acquired, the

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

difference is recognized in profit or loss.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's CGUs that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. Each unit or group of units to which the goodwill is so allocated represents the lowest level within the Group at which the goodwill is monitored for internal management purpose and is not larger than an operating segment.

Where goodwill forms part of a CGU and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation. Goodwill disposed of in this circumstance is measured based on the relative recoverable amounts of the operation disposed of and the portion of the CGU retained.

5. Significant Accounting Judgments and Major Sources of Estimation Uncertainty

The preparation of the Group's consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that may result in significant risks for a material adjustment to the carrying amounts of assets and liabilities within the next fiscal year are discussed below.

(1) Fair value of financial instruments

Where the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be derived from active markets, they are determined using valuation techniques including income approach (for example, the discounted cash flows model) or the market approach. Changes in assumptions of those models could affect the fair value of the reported financial instruments. Please refer to Note 12 for details.

(2) Receivables – impairment loss estimate

From January 1, 2018

The Group estimates the impairment loss of receivables by measuring the lifetime expected credit losses. Credit loss is calculated as the present value of the difference between contractual cash flows that are due to the Group under contracts (carrying amount) and cash flows the Group expects to receive (assessing the forward-looking information). For short-term receivables, as the discount effect is not significant, credit loss is measured using the undiscounted difference. Less-than-expected future cash flows could result in significant impairment charges. Please refer to Note 6(21) for details.

(3) Inventories

The estimates of net realizable value for inventory take into account inventory spoilage, total or partial obsolescence or selling price declines. They are based on the most reliable evidence available when those estimates are made. Please refer to Note 6(5) for details.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(4) Post-employment benefit plans

The cost of pension plan and the present value of defined benefit obligation within the post-employment benefit plans are determined using actuarial valuations. An actuarial valuation involves making various assumptions, including the discount rates and expected future salary changes. The assumptions used for measuring pension cost and defined benefit obligation are disclosed in Note 6(17).

(5) Share-based payment transactions

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments on the grant date. Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model, including the expected life of the share option, volatility and dividend yield, and making assumptions about them. The assumptions and models used for estimating the fair value of share-based payment transactions are disclosed in Note 6(19).

(6) Income tax

Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Given the wide range of international business relationships and the long-term nature and complexity of existing contractual agreements, differences between the actual results and the assumptions made or future changes to such assumptions could necessitate future adjustments to tax benefit and expense already recorded. The Group establishes provisions, based on reasonable estimates, for possible consequences of audits by the tax authorities of the respective countries in which it operates.

Deferred income tax assets are recognized for all carryforward of unused tax losses and unused tax credits and deductible temporary differences to the extent that it is probable that taxable profit will be available or there are sufficient taxable temporary differences against which the unused tax losses, unused tax credits or deductible temporary differences can be utilized. The amount of deferred income tax assets to be recognized is based upon the likely timing and the level of future taxable income and taxable temporary differences together with future tax planning strategies. Deferred income tax assets unrecognized by the Group as of December 31, 2018 are disclosed in Note 6(25).

6. Details of Significant Accounts

(1) Cash and cash equivalents

| | December 31, 2018 | December 31, 2017 |
|---------------|----------------------|----------------------|
| Cash on hand | \$ 688 | \$ 652 |
| Bank deposits | 1,861,898 | 1,933,624 |
| Total | <u>\$ 1,862,586</u> | <u>\$ 1,934,276</u> |

(2) Financial assets at fair value through profit or loss - current

| | December 31, 2018 | December 31, 2017 (Note) |
|---|-----------------------------|-----------------------------|
| Mandatorily at fair value through profit or loss: | | |
| Derivative instruments not designated in a hedging relationship | | |
| - Forward foreign exchange contracts | \$ 13,659 | |
| - Cross-currency swap contracts | 2,358 | |
| Stocks | 20,421 | |
| Total | <u>\$ 36,438</u> | |
| | December 31, 2018 (Note) | December 31, 2017 |
| Held for trading: | | |
| Derivative instruments not designated in a hedging relationship | | |
| - Forward foreign exchange contracts | | \$ 214 |
| - Cross-currency swap contracts | | 572 |
| Non-derivative financial assets - Stocks | | 16,677 |
| Total | | <u>\$ 17,463</u> |

Note: The Group adopted IFRS 9 on January 1, 2018 and chose not to restate the comparative periods in accordance with the transitional provisions of IFRS 9.

The Group's financial assets at fair value through profit or loss were not pledged.

(3) Notes receivable, net

| | December 31, 2018 | December 31, 2017 |
|-----------------------|----------------------|----------------------|
| Notes receivable, net | <u>\$ 1,218,019</u> | <u>\$ 2,027,778</u> |

The Group's notes receivables were not pledged.

The Group adopted IFRS 9 for impairment assessment on January 1, 2018. Please refer to Note 6(21) for details on loss allowance and Note 12 for information concerning credit risk.

(4) Accounts receivable, net

| | December 31, 2018 | December 31, 2017 |
|----------------------|----------------------|----------------------|
| Accounts receivable | \$ 3,755,856 | \$ 2,965,128 |
| Less: loss allowance | (77,758) | (216,495) |
| Net | <u>\$ 3,678,098</u> | <u>\$ 2,748,633</u> |

A. The credit terms of accounts receivable are generally set at 60 to 150 days from the end of month. The Group adopted IFRS 9 for impairment assessment on January 1, 2018. Please refer to Note 6(21) for loss allowance for the year ended December 31, 2018. Prior to January 1, 2018, IAS 39 was adopted for impairment assessment. The movements in the allowance for impairment of accounts receivable for the year ended December 31, 2017 were as follows (please refer to Note 12 for credit risk disclosure):

| | December 31, 2017 |
|---------------------------------|----------------------|
| Beginning balance | \$ 211,697 |
| Charge for the year | 8,967 |
| Write off | (5,224) |
| Effect of exchange rate changes | 1,055 |
| Ending balance | <u>\$ 216,495</u> |

B. Ageing analysis of net accounts receivable:

| | December 31, 2017 |
|-------------------------------|----------------------|
| Neither past due nor impaired | <u>\$ 2,053,205</u> |
| Past due but not impaired | |
| ≤ 120 days | 462,019 |
| 121 to 180 days | 201,612 |
| ≥ 181 days | 31,797 |
| Total | <u>\$ 2,748,633</u> |

C. The Group entered into factoring agreements without recourse with banks. The banks would engage in factoring with respect to accounts receivable selected. The information of factoring transactions was as follows:

The Group had no factoring agreements as of December 31, 2018 and factoring transactions as of December 31, 2017 was as follows:

| December 31, 2017 | | | |
|-------------------------------------|-------------------------|------------------|---|
| Amount of Accounts Receivable | Amount of Factoring | Condition | Unreceived Amount (Recorded as Other Receivables) |
| US\$ 38,680 thousand | US\$ 38,680 thousand | without recourse | - |

D. The Group's accounts receivables were not pledged.

(5) Inventories, net

| | December 31, 2018 | December 31, 2017 |
|------------------------|----------------------|----------------------|
| Raw materials | \$ 572,527 | \$ 585,584 |
| Inventories in transit | 81,199 | 171,759 |
| Supplies | 8,568 | 4,966 |
| Work in process | 52,921 | 52,701 |
| Finished goods | 426,139 | 619,307 |
| Merchandise | 322,953 | 191,969 |
| Total | <u>\$ 1,464,307</u> | <u>\$ 1,626,286</u> |

Expenses or income recognized were as follows:

| | Years Ended December 31 | |
|--|-------------------------|---------------------|
| | 2018 | 2017 |
| Cost of inventories sold | \$ 7,597,252 | \$ 9,043,138 |
| (Gain on recovery) write-down of inventory | (238) | 29,753 |
| Loss on inventory write-off | 79,497 | 10,504 |
| Revenue from sale of scraps | (26,504) | (25,080) |
| Cost of revenue | <u>\$ 7,650,007</u> | <u>\$ 9,058,315</u> |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

For the year ended December 31, 2018, gain on inventory value recovery due to a decrease in allowance for inventory valuation losses from price recovery of inventories with allowance for inventory valuation losses at beginning of period, inventories sold or inventories used amounted to NT\$238 thousand.

The aforementioned inventories were not pledged.

(6) Financial assets at fair value through other comprehensive income - non-current

| | December 31, 2018 | December 31, 2017 (Note) |
|---|----------------------|-----------------------------|
| Equity instrument investments at fair value through other comprehensive income – non-current: | | |
| Non-listed (OTC) stocks | \$ — | |

Note: The Group adopted IFRS 9 on January 1, 2018 and chose not to restate the comparative periods in accordance with the transitional provisions of IFRS 9.

The Group's financial assets at fair value through other comprehensive income were not pledged.

(7) Financial assets carried at cost - non-current

| | December 31, 2017 |
|------------------------------|----------------------|
| Stocks | \$ 6,600 |
| Less: accumulated impairment | (6,600) |
| Net | \$ — |

Note: The Group adopted IFRS 9 on January 1, 2018 and chose not to restate the comparative periods in accordance with the transitional provisions of IFRS 9.

The aforementioned non-listed (OTC) stocks held by the Group were recognized in accordance with IAS 39 prior to January 1, 2018. Since the range of reasonable fair value estimates was significant and the probabilities of various estimates could not be reasonably assessed, those stocks could not be measured at fair value. Thus, they were measured at cost.

The Group's financial assets carried at cost were not pledged.

(8) Investments accounted for under the equity method

| | December 31, 2018 | | December 31, 2017 | |
|---|-------------------|----------------------------|-------------------|----------------------------|
| | Amount | Percentage of Ownership | Amount | Percentage of Ownership |
| Investments in associates: | | | | |
| Innovision FlexTech Corp. | \$ 51,470 | 15.07% | \$ 31,518 | 15.67% |
| Less: accumulated impairment – Innovision FlexTech Corp. | — | | (31,518) | |
| Net | \$ 51,470 | | \$ — | |

The aforementioned investments accounted for under the equity method were not pledged.

A. The shares of profit or loss of the associates accounted for under the equity method for the years ended December 31, 2018 and 2017 were as follows:

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

| Investee | Years Ended December 31 | |
|---------------------------|-------------------------|------|
| | 2018 | 2017 |
| Innovision FlexTech Corp. | \$ 19,666 | \$ — |

B. In December 2017, the Group participated in the capital increase of Innovision FlexTech Corp. (Innovision) and subscribed at a percentage different from its existing ownership percentage. Thus, the shareholding percentage reduced from 16.72% to 15.67%. In February 2018, the Group subscribed in the capital increase of Innovision at a percentage different from its existing ownership percentage. The shareholding percentage dropped from 15.67% to 15.07%. The Group evaluated and concluded that it still had significant influence over Innovision; thus, this investment was accounted for using the equity method.

C. The summarized financial information of the Group's investments in associates was as follows:

| | December 31, 2018 | December 31, 2017 |
|-------------------|----------------------|----------------------|
| Total assets | \$ 471,150 | \$ 331,496 |
| Total liabilities | \$ 129,608 | \$ 73,767 |

| | Years Ended December 31 | |
|------------|-------------------------|------------|
| | 2018 | 2017 |
| Revenue | \$ 333,264 | \$ 190,056 |
| Net income | \$ 72,099 | \$ 12,587 |

D. For investments accounted for under the equity method, the Group recognized a gain on reversal of impairment of NT\$31,518 thousand for the year ended December 31, 2018 based on the assessment of future recoverable amount.

E. The aforementioned recoverable amount was measured at fair value less costs of disposal and the fair value was determined using the market approach. The recent financing activities of the investees, the technology development status, companies with similar attributes, market conditions and other economic indicators shall all be considered. This was a level 3 fair value measurement.

(9) Property, plant and equipment

| | December 31, 2018 | December 31, 2017 |
|---|----------------------|----------------------|
| Land | \$ 100,843 | \$ 100,843 |
| Buildings | 1,154,006 | 966,217 |
| Machinery and equipment | 924,014 | 896,022 |
| Hydropower equipment | 186,331 | 118,143 |
| Testing equipment | 151,061 | 128,173 |
| Miscellaneous equipment | 93,415 | 82,032 |
| Construction in progress and equipment awaiting inspection | 411,218 | 585,028 |
| Net | \$ 3,020,888 | \$ 2,876,458 |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

| | As of January 1, 2018 | Additions | Disposals | Reclassification | Impairment Loss | Effect of Exchange Rate Changes | As of December 31, 2018 |
|--|-----------------------------|-------------------|--------------------|-------------------|-----------------|---------------------------------------|-------------------------------|
| <u>Cost</u> | | | | | | | |
| Land | \$ 100,843 | \$ — | \$ — | \$ — | \$ — | \$ — | \$ 100,843 |
| Buildings | 1,438,659 | 7,026 | (213) | 257,927 | — | (10,920) | 1,692,479 |
| Machinery and equipment | 2,552,155 | 62,224 | (18,417) | 124,453 | — | (9,118) | 2,711,297 |
| Hydropower equipment | 398,778 | 8,319 | — | 81,255 | — | (3,098) | 485,254 |
| Testing equipment | 251,175 | 10,822 | (2,395) | 37,366 | — | (499) | 296,469 |
| Miscellaneous equipment | 363,839 | 10,565 | (9,588) | 21,654 | — | (1,790) | 384,680 |
| Total | <u>\$ 5,105,449</u> | <u>\$ 98,956</u> | <u>\$ (30,613)</u> | <u>\$ 522,655</u> | <u>\$ —</u> | <u>\$ (25,425)</u> | <u>\$ 5,671,022</u> |
| <u>Accumulated depreciation and impairment</u> | | | | | | | |
| Buildings | \$ 472,442 | \$ 70,051 | \$ (213) | \$ — | \$ — | \$ (3,807) | \$ 538,473 |
| Machinery and equipment | 1,656,133 | 156,223 | (18,417) | — | — | (6,656) | 1,787,283 |
| Hydropower equipment | 280,635 | 20,304 | — | — | — | (2,016) | 298,923 |
| Testing equipment | 123,002 | 24,757 | (1,968) | — | — | (383) | 145,408 |
| Miscellaneous equipment | 281,807 | 20,127 | (9,210) | — | — | (1,459) | 291,265 |
| Total | <u>\$ 2,814,019</u> | <u>\$ 291,462</u> | <u>\$ (29,808)</u> | <u>\$ —</u> | <u>\$ —</u> | <u>\$ (14,321)</u> | <u>\$ 3,061,352</u> |
| Construction in progress and equipment awaiting inspection | 585,028 | 350,226 | — | (523,052) | — | (984) | 411,218 |
| Net | <u>\$ 2,876,458</u> | | | | | | <u>\$ 3,020,888</u> |
| | | | | | | | |
| | As of January 1, 2017 | Additions | Disposals | Reclassification | Impairment Loss | Effect of Exchange Rate Changes | As of December 31, 2017 |
| <u>Cost</u> | | | | | | | |
| Land | \$ 100,843 | \$ — | \$ — | \$ — | \$ — | \$ — | \$ 100,843 |
| Buildings | 1,415,481 | 4,827 | — | 23,503 | — | (5,152) | 1,438,659 |
| Machinery and equipment | 2,488,501 | 39,648 | (14,369) | 42,635 | — | (4,260) | 2,552,155 |
| Hydropower equipment | 370,939 | 8,157 | (19) | 21,081 | — | (1,380) | 398,778 |
| Testing equipment | 223,526 | 15,623 | (3,037) | 15,309 | — | (246) | 251,175 |
| Miscellaneous equipment | 334,839 | 10,623 | (6,272) | 25,430 | — | (781) | 363,839 |
| Total | <u>\$ 4,934,129</u> | <u>\$ 78,878</u> | <u>\$ (23,697)</u> | <u>\$ 127,958</u> | <u>\$ —</u> | <u>\$ (11,819)</u> | <u>\$ 5,105,449</u> |
| <u>Accumulated depreciation and impairment</u> | | | | | | | |
| Buildings | \$ 410,029 | \$ 63,402 | \$ — | \$ — | \$ — | \$ (989) | \$ 472,442 |
| Machinery and equipment | 1,519,451 | 153,192 | (14,342) | — | — | (2,168) | 1,656,133 |
| Hydropower equipment | 262,438 | 18,819 | (19) | — | — | (603) | 280,635 |
| Testing equipment | 108,104 | 17,518 | (2,489) | — | — | (131) | 123,002 |
| Miscellaneous equipment | 267,413 | 20,769 | (5,952) | — | — | (423) | 281,807 |
| Total | <u>\$ 2,567,435</u> | <u>\$ 273,700</u> | <u>\$ (22,802)</u> | <u>\$ —</u> | <u>\$ —</u> | <u>\$ (4,314)</u> | <u>\$ 2,814,019</u> |
| Construction in progress and equipment awaiting inspection | 422,826 | 290,317 | — | (128,078) | — | (37) | 585,028 |
| Net | <u>\$ 2,789,520</u> | | | | | | <u>\$ 2,876,458</u> |

Please refer to Note 8 for property, plant and equipment pledged.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(10) Intangible assets

| | December 31, 2018 | December 31, 2017 |
|---------------|----------------------|----------------------|
| Trademarks | \$ 354 | \$ 414 |
| Patents | 6,848 | 7,780 |
| Software cost | 37,725 | 43,403 |
| Goodwill | 69,781 | 69,781 |
| Total | \$ 114,708 | \$ 121,378 |

| | As of January 1, 2018 | Additions | Reclassification | Effect of Exchange Rate Changes | As of December 31, 2018 |
|---------------|-----------------------------|------------------|------------------|---------------------------------------|-------------------------------|
| <u>Cost</u> | | | | | |
| Trademarks | \$ 672 | \$ — | \$ — | \$ — | \$ 672 |
| Patents | 44,247 | 775 | — | — | 45,022 |
| Software cost | 128,557 | 9,673 | 396 | (307) | 138,319 |
| Goodwill | 69,781 | — | — | — | 69,781 |
| Total | \$ 243,257 | \$ 10,448 | \$ 396 | \$ (307) | \$ 253,794 |

Accumulated amortization
and impairment

| | | | | | |
|---------------|-------------------|------------------|-------------|-----------------|-------------------|
| Trademarks | \$ 258 | \$ 60 | \$ — | \$ — | \$ 318 |
| Patents | 36,467 | 1,707 | — | — | 38,174 |
| Software cost | 85,154 | 15,628 | — | (188) | 100,594 |
| Total | \$ 121,879 | \$ 17,395 | \$ — | \$ (188) | \$ 139,086 |
| Net | \$ 121,378 | | | | \$ 114,708 |

| | As of January 1, 2017 | Additions | Reclassification | Effect of Exchange Rate Changes | As of December 31, 2017 |
|---------------|-----------------------------|------------------|------------------|---------------------------------------|-------------------------------|
| <u>Cost</u> | | | | | |
| Trademarks | \$ 583 | \$ 89 | \$ — | \$ — | \$ 672 |
| Patents | 42,202 | 2,045 | — | — | 44,247 |
| Software cost | 108,294 | 20,412 | — | (149) | 128,557 |
| Goodwill | 69,781 | — | — | — | 69,781 |
| Total | \$ 220,860 | \$ 22,546 | \$ — | \$ (149) | \$ 243,257 |

Accumulated amortization
and impairment

| | | | | | |
|---------------|-------------------|------------------|-------------|----------------|-------------------|
| Trademarks | \$ 198 | \$ 60 | \$ — | \$ — | \$ 258 |
| Patents | 34,855 | 1,612 | — | — | 36,467 |
| Software cost | 72,209 | 13,016 | — | (71) | 85,154 |
| Total | \$ 107,262 | \$ 14,688 | \$ — | \$ (71) | \$ 121,879 |
| Net | \$ 113,598 | | | | \$ 121,378 |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(11) Other non-current assets

| | December 31, 2018 | December 31, 2017 |
|---|----------------------|----------------------|
| Long-term prepaid rent (Land use rights) | \$ 137,374 | \$ 20,218 |
| Refundable deposits | 16,879 | 24,100 |
| Other non-current assets - other | 18,198 | 27,708 |
| Total | <u>\$ 172,451</u> | <u>\$ 72,026</u> |

(12) Impairment testing of goodwill

Goodwill acquired through business combinations was allocated to each of the CGUs, which were expected to benefit from synergies. Impairment evaluation of recoverable amount of goodwill was conducted at each year end. The recoverable amount of the CGU was determined based on value-in-use which was calculated using cash flow projections from financial budgets approved by management covering a five-year period discounted at a pre-tax rate. The projected cash flows had been updated to reflect the change in demand of relevant products. As a result of the analysis, the Company determined that the goodwill of NT\$69,781 thousand was not impaired.

Key assumptions used in value-in-use calculations

Discount rates – Discount rates reflect the current market assessment of the risks specific to each CGU (including the time value of money and the risks specific to the asset not included in the cash flow estimates). The Group used the pre-tax discount rate to reflect the relevant specific risk in the operating segment.

Sensitivity to changes in assumptions

The management believes that no reasonably possible change in any of the above key assumptions would cause the carrying value of the unit to materially exceed its recoverable amount.

(13) Short-term loans

| | December 31, 2018 | December 31, 2017 |
|----------------------|----------------------|----------------------|
| Unsecured bank loans | <u>\$ 1,362,054</u> | <u>\$ 656,596</u> |

The interest rates of loans were 0.74% to 3.50% and 1.69% to 4.57% as of December 31, 2018 and 2017, respectively.

(14) Financial liabilities at fair value through profit or loss - current

| | December 31, 2018 | December 31, 2017 |
|--|----------------------|----------------------|
| Held for trading: | | |
| Derivative financial instruments not designated in a hedging relationship | | |
| - Forward foreign exchange contracts | \$ 2,471 | \$ 13,058 |
| - Foreign exchange swap contracts | 185 | 224 |
| - Cross-currency swap contracts | — | 69 |
| | <u>\$ 2,656</u> | <u>\$ 13,351</u> |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(15) Lease payable

Some equipment of the Group was held under finance lease where the lessee had the option to purchase the equipment. The reconciliation of total future minimum lease payments and their present value was as follows:

| | December 31, 2018 | December 31, 2017 |
|--|----------------------|----------------------|
| <u>Total minimum lease payments</u> | | |
| Less than 1 year | \$ 959 | \$ 981 |
| 1 to 5 years (excluding) | 1,730 | 2,750 |
| | <u>2,689</u> | <u>3,731</u> |
| Less: Future financial expense | (246) | (593) |
| Present value of minimum lease payments | <u>\$ 2,443</u> | <u>\$ 3,138</u> |
| <u>Present value of minimum lease payments</u> | | |
| Less than 1 year | \$ 758 | \$ 639 |
| 1 to 5 years (excluding) | 1,685 | 2,499 |
| | <u>\$ 2,443</u> | <u>\$ 3,138</u> |

(16) Long-term loans

| | December 31, 2018 | December 31, 2017 |
|---------------------------------------|----------------------|----------------------|
| Secured loans | \$ 46,932 | \$ 62,011 |
| Revolving loans | 295,000 | 193,685 |
| Syndicated loans | — | — |
| Total | <u>341,932</u> | <u>255,696</u> |
| Less: current portion | (12,258) | (44,825) |
| Less: unamortized syndicated loan fee | — | — |
| Net | <u>\$ 329,674</u> | <u>\$ 210,871</u> |

- A. The interest rates of loans were 0.88% to 1.97% and 0.85% to 2.47% as of December 31, 2018 and 2017, respectively.
- B. Please refer to Note 8 for collateral of the long-term loans.
- C. In January 2016, the Group entered into a syndicated loan agreement with ten financial institutions, including the Bank of Taiwan (bookrunner), for a loan facility of NT\$2.5 billion or the equivalent in U.S. dollars. (The Group applied to lower the credit to NT\$1.5 billion or the equivalent in U.S. dollars in July 2017.) The contract term is five years from the initial drawdown date, i.e. June 2016 to June 2021. The credit term of the agreement was mid-term loans - current. During the loan term, the Group is required to calculate and maintain the following financial ratios at an agreed level based on the consolidated financial statements audited by CPAs every six months: current ratio, debt ratio, interest coverage ratio and tangible net value. The Group has abided by those terms.

(17) Post-employment benefit plans

A. Defined contribution plan

Expenses under the defined contribution plan for the years ended December 31, 2018 and 2017 were NT\$26,303 thousand and NT\$23,878 thousand, respectively.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

B. Defined benefit plan

Expenses under the defined benefit plan were as follows:

| Financial Statement Account | Years Ended December 31 | |
|-------------------------------------|-------------------------|------------------|
| | 2018 | 2017 |
| Operating costs | \$ 5,232 | \$ 7,339 |
| Sales and marketing expenses | 598 | 1,055 |
| General and administrative expenses | 3,437 | 9,123 |
| Research and development expenses | 3,415 | 3,318 |
| Total | <u>\$ 12,682</u> | <u>\$ 20,835</u> |

C. Accumulated amounts of actuarial gain or loss recognized under other comprehensive income were as follows:

| | Years Ended December 31 | |
|------------------------|-------------------------|-------------------|
| | 2018 | 2017 |
| Beginning balance | \$ 101,009 | \$ 125,139 |
| Actuarial gain or loss | (55,488) | (24,130) |
| Ending balance | <u>\$ 45,521</u> | <u>\$ 101,009</u> |

D. Reconciliation of defined benefit obligation at present value and plan asset at fair value was as follows:

| | Years Ended December 31 | |
|---|-------------------------|-------------------|
| | 2018 | 2017 |
| Present value of defined benefit obligation | \$ 172,041 | \$ 213,669 |
| Fair value of plan assets | (33,618) | (29,545) |
| Funded status | 138,423 | 184,124 |
| Net defined benefit liability | <u>\$ 138,423</u> | <u>\$ 184,124</u> |

E. Changes in the present value of the defined benefit obligation were as follows:

| | Years Ended December 31 | |
|----------------------------|-------------------------|-------------------|
| | 2018 | 2017 |
| Balance, beginning of year | \$ 213,669 | \$ 222,272 |
| Current service cost | 9,644 | 11,782 |
| Past service cost | — | 5,531 |
| Interest cost | 3,419 | 4,001 |
| Actuarial gain or loss | (54,691) | (24,386) |
| Benefits paid | — | (5,531) |
| Balance, end of year | <u>\$ 172,041</u> | <u>\$ 213,669</u> |

F. Changes in the fair value of the plan assets were as follows:

| | Years Ended December 31 | |
|-----------------------------|-------------------------|------------------|
| | 2018 | 2017 |
| Balance, beginning of year | \$ 29,545 | \$ 31,996 |
| Return on plan assets | 472 | 576 |
| Contributions from employer | 2,804 | 2,760 |
| Actuarial gain or loss | 797 | (256) |
| Benefits paid | — | (5,531) |
| Balance, end of year | <u>\$ 33,618</u> | <u>\$ 29,545</u> |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

- G. The Company expects to make contributions of NT\$8,962 thousand to the defined benefit plan in the following 12 months as of December 31, 2018.
- H. The major categories of plan assets as a percentage of the fair value of total plan assets were as follows:

| | Pension Plan (%) | |
|------|----------------------|----------------------|
| | December 31, 2018 | December 31, 2017 |
| Cash | 100% | 100% |

The Company's actual return on plan assets were NT\$1,269 thousand and NT\$320 thousand for the years ended December 31, 2018 and 2017, respectively.

The expected rate of return on plan assets is determined based on historical trend and analysts' expectation on the asset's return in its market over the obligation period. Furthermore, the utilization of the fund by the labor pension fund supervisory committee and the fact that the minimum earnings are guaranteed to be no less than the earnings attainable from local banks' two-year time deposits are also taken into consideration in determining the expected rate of return on plan assets.

- I. The principal assumptions used in determining the Company's defined benefit plan were shown below:

| | December 31, 2018 | December 31, 2017 |
|--|----------------------|----------------------|
| Discount rate | 1.31% | 1.60% |
| Expected rate of return on plan assets | 1.31% | 1.60% |
| Expected rate of salary increases | 3.00% | 4.50% |

- J. A 0.5% change in the discount rate would result in the following:

| | Years Ended December 31 | | | |
|--|-------------------------|------------------|------------------|------------------|
| | 2018 | | 2017 | |
| | 0.5% Increase | 0.5% Decrease | 0.5% Increase | 0.5% Decrease |
| Effect on the aggregate current service cost and interest cost | \$ (205) | \$ 131 | \$ (502) | \$ 453 |
| Effect on the present value of defined benefit obligation | (14,613) | 16,194 | (19,506) | 21,744 |

- K. Other information on the defined benefit plan was as follows:

| | Years Ended December 31 | |
|---|-------------------------|------------|
| | 2018 | 2017 |
| Present value of defined benefit obligation, ending balance | \$ 172,041 | \$ 213,669 |
| Fair value of plan assets, ending balance | (33,618) | (29,545) |
| Surplus/deficit of plan, ending balance | \$ 138,423 | \$ 184,124 |
| Experience adjustments on plan liabilities | \$ (15,345) | \$ (9,037) |
| Experience adjustments on plan assets | \$ (797) | \$ 256 |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(18) Equity

A. Capital

- (a) The Company's authorized capital was NT\$3,000,000 thousand, each at a par value of NT\$10, divided into 300,000 thousand shares (including 15,000 thousand shares with the amount of NT\$150,000 thousand reserved for the exercise of employee stock options, preferred stock with warrants and bond with warrants) as of December 31, 2018 and 2017.
- (b) The Company's issued capital was NT\$2,091,197 thousand and NT\$2,087,802 thousand, each at a par value of NT\$10, divided into 209,120 thousand shares and 208,780 thousand shares as of December 31, 2018 and 2017, respectively.

B. Capital surplus

| | December 31, 2018 | December 31, 2017 |
|-----------------------------|----------------------|----------------------|
| Additional paid-in capital | \$ 1,042,894 | \$ 1,036,041 |
| Premium from merger | 262,500 | 262,500 |
| Donated assets | 1,970 | 1,970 |
| Treasury stock transactions | 27,280 | 27,280 |
| Others | 111,995 | 113,548 |
| Total | \$ 1,446,639 | \$ 1,441,339 |

According to laws and regulations, capital surplus shall not be used except for making good the deficit of the company. When a company incurs no loss, it may distribute the capital surplus related to the income derived from the issuance of new shares at a premium or income from endowments received by the company as stock dividends up to a certain percentage of paid-in capital. The said capital surplus could also be distributed in the form of cash dividends to its shareholders in proportion to the number of shares being held by each of them.

C. Treasury stocks

As of December 31, 2018 and 2017, the number of treasury stocks held by the Company was 0 thousand shares with the amount of NT\$0 thousand.

The changes of treasury stocks in the years ended December 31, 2018 and 2017 were as follows:

| Reasons of Repurchase | As of January 1 | Increase | Decrease | As of December 31 |
|--------------------------|-----------------------|----------|-----------------------|----------------------|
| <u>2018</u> | | | | |
| Transferred to employees | — | — | — | — |
| <u>2017</u> | | | | |
| Transferred to employees | 2,318 thousand shares | — | 2,318 thousand shares | — |

Pursuant to the Securities and Exchange Act, the number of shares repurchased cannot exceed ten percent of the shares outstanding and the repurchase amount shall not exceed

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

the sum of retained earnings, share premium and realized capital surplus. The shares bought back by the Company to be transferred to employees shall be transferred within three years from the buyback date. Shares not transferred within the said time limit shall be deemed as unissued shares and must be cancelled. Furthermore, treasury stocks shall not be pledged as collateral and they do not have shareholders' rights before being transferred.

D. Appropriation of profits and dividend policies

The Articles of Incorporation state that current year's earnings, if any, shall be distributed in the following order:

- (a) Taxes and dues.
- (b) Deficit compensation.
- (c) 10% of net profit as legal capital reserves. However, this shall not apply when the accumulated legal capital reserve has equaled the total capital.
- (d) Special capital reserve appropriated or reversed as stipulated by relevant laws and regulations or the competent securities authorities.
- (e) For the remaining profits, if any, the Board of Directors shall draft a proposal for the distribution of bonus to shareholders and submit it to the shareholders' meeting for resolution.

After taking into account the environment and development stage of the Company, the needs of capital in the future, long-term financial planning and shareholders' demand for cash, the Board of Directors shall draw up an earnings distribution proposal based on the distributable earnings and submit it to the shareholders' meeting for approval. At least forty percent of the distributable earnings shall be appropriated as shareholders' dividends. The cash dividend shall not be lower than 10 percent of the total dividends and shall be capped at 100 percent.

Following the adoption of IFRS, the Company complies with Order No. Jin-Guan-Zheng-Fa-1010012865 issued by the FSC on April 6, 2012, which sets out the following provisions: On a public company's first-time adoption of the IFRS, for any unrealized revaluation gains and cumulative translation adjustments (gains) recorded to shareholders' equity that the company elects to transfer to retained earnings by application of the exemption under IFRS 1, the company shall set aside an equal amount of special capital reserve. Following a company's adoption of the IFRS for the preparation of its financial reports, when distributing distributable earnings, if the company has already set aside special capital reserve according to the requirements in the preceding point, it shall set aside supplemental special capital reserve based on the difference between the amount already set aside and other net deductions from shareholders' equity. For any subsequent reversal of other net deductions from shareholders' equity, the amount reversed may be distributed.

As of December 31, 2018 and 2017, special capital reserve set aside for the first-time adoption of IFRS amounted to NT\$75,546 thousand and NT\$102,158 thousand, respectively. Furthermore, the Company reversed NT\$26,612 thousand of special capital reserve recognized to undistributed earnings during the year ended December 31, 2018 as the consolidated entity disposed of related assets.

Information about the appropriations of 2017 and 2016 earnings approved in the

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

shareholders' meetings on May 29, 2018 and May 26, 2017, respectively, was as follows:

| | Appropriation of Earnings | | Dividend per Share (NT\$) | |
|-----------------------------------|---------------------------|-------------------|---------------------------|---------|
| | 2017 | 2016 | 2017 | 2016 |
| Legal capital reserve | \$ 73,459 | \$ 57,968 | - | - |
| Cash dividends - common stocks | 522,799 | 412,254 | \$ 2.50 | \$ 2.00 |
| Total | <u>\$ 596,258</u> | <u>\$ 470,222</u> | | |

Please refer to Note 6(23) for information on the accrual basis and the amounts recognized for compensation to employees and remuneration to directors.

E. Non-controlling interests (NCI)

| | Years Ended December 31 | |
|--|-------------------------|-------------------|
| | 2018 | 2017 |
| Beginning balance | \$ 112,212 | \$ 100,310 |
| Net income attributable to NCI | 7,165 | 11,956 |
| Other comprehensive income attributable to NCI: | | |
| Exchange differences arising on translation of foreign operations | (166) | (54) |
| Ending balance | <u>\$ 119,211</u> | <u>\$ 112,212</u> |

(19) Share-based payment plans

On February 25, 2010, the Company resolved at the Board of Directors' meeting to issue employee stock options with a total number of 2,355 units. Each unit entitles an optionee to subscribe to 1,000 shares of the Company's common stock. The chairperson is authorized by the Board to set the actual grant date. If a consensus was not reached regarding all terms and conditions, the grant date would be the date when consensus for all were reached (April 30, 2010). Settlement upon exercise of the options will be made through issuance of new shares by the Company. An optionee may exercise the options in accordance with certain schedules and percentages prescribed by the plan two years from the grant date. Expense of the compensatory employee stock option plan for the year ended December 31, 2018 was NT\$0 thousand.

There have been no cancellations or modifications to any of the employee stock option plans by December 31, 2018.

| | Years Ended December 31 | | | |
|------------------------------------|-------------------------|--|------------|--|
| | 2018 | | 2017 | |
| | Quantity | Weighted Average Exercise Price per Share (NT\$) | Quantity | Weighted Average Exercise Price per Share (NT\$) |
| Stock options | | | | |
| Outstanding at beginning of period | 273 | \$ 35.10 | 952 | \$ 36.80 |
| Granted | - | - | - | - |
| Forfeited | - | - | - | - |
| Exercised | (273) | 35.10 | (522) | 35.77 |
| Expired | - | - | (157) | - |
| Outstanding at end of period | <u>-</u> | - | <u>273</u> | 35.10 |
| Exercisable at end of period | <u>-</u> | - | <u>273</u> | 35.10 |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

Information on the aforementioned employee stock options outstanding as of December 31, 2018 and 2017 was as follows:

| Date of Grant | Weighted Average Remaining Contractual Years | |
|----------------|--|----------------------|
| | December 31, 2018 | December 31, 2017 |
| April 30, 2010 | - | 0.33 |

(20) Revenue

| | Years Ended December 31 | |
|---------------|-------------------------|---------------|
| | 2018 (Note) | 2017 |
| Sale of goods | \$ 9,643,051 | \$ 11,192,892 |

Note: The Group adopted IFRS 15 for the recognition of revenue from contracts with customers on January 1, 2018 and chose to recognize the cumulative effect of the first-time adoption on January 1, 2018.

The Group adopted IFRS 15 for the recognition of revenue from contracts with customers on January 1, 2018. Information concerning revenue from contracts with customers for the year ended December 31, 2018 was as follows:

Contract liabilities - current

| | Beginning Balance | Ending Balance | Difference |
|---------------|----------------------|-------------------|------------|
| Sale of goods | \$ 2,571 | \$ 2,372 | \$ (199) |

The decrease in the balance of contract liabilities was mostly due to the satisfaction of performance obligations in 2018, and of which NT\$2,528 thousand was beginning balance recognized as revenue during this period.

(21) Reversal of expected credit loss

| | Years Ended December 31 | |
|---|-------------------------|-------------|
| | 2018 | 2017 (Note) |
| Operating expenses – Reversal of expected credit loss | | |
| Accounts receivable | \$ (136,144) | |

Note: The Group adopted IFRS 9 on January 1, 2018 and chose not to restate the comparative periods in accordance with the transitional provisions of IFRS 9.

Please refer to Note 12 for information concerning credit risk.

For receivables (including notes and accounts receivables), the Group measured the loss allowance at an amount equal to lifetime expected credit losses. The assessment on the loss allowance as of December 31, 2018 was as follows:

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

Receivables were grouped by considering the credit ratings of counterparties, geographical regions and industry sectors, and the loss allowance was measured by adopting a provision matrix. Details were as follows:

| | Not Past Due (Note) | Past Due | | | Total |
|------------------------------------|------------------------|-------------------|----------------|------------------|--------------|
| | | Within 90 Days | 91-180 Days | Over 181 Days | |
| Gross carrying amount | \$ 4,597,619 | \$ 250,235 | \$ 66,095 | \$ 59,926 | \$ 4,973,875 |
| Loss ratio | 0%~1% | 3%~20% | 20%~50% | 50%~100% | |
| Lifetime expected credit losses | 17,586 | 13,086 | 16,040 | 31,046 | 77,758 |
| Subtotal | \$ 4,580,033 | \$ 237,149 | \$ 50,055 | \$ 28,880 | \$ 4,896,117 |

Note: None of the Group's notes receivables was overdue.

The movements in the loss allowance for receivables in the year ended December 31, 2018 were as follows:

| | Receivables |
|---------------------------------|-------------|
| Beginning balance | \$ 216,495 |
| Reversal in the current period | (136,144) |
| Write off | (1,586) |
| Effect of exchange rate changes | (1,007) |
| Ending balance | \$ 77,758 |

(22) Operating leases

The Group entered into commercial property leases which were non-cancellable operating lease agreements. The average duration was between one to ten years. Some lease agreements had renewal options.

Total future minimum lease payments were as follows:

| | 2018.12.31 | 2017.12.31 |
|--|------------|------------|
| Less than 1 year | \$ 23,793 | \$ 21,634 |
| More than 1 year but less than 5 years | 42,216 | 39,185 |
| More than 5 years | 18,481 | 13,796 |
| Total | \$ 84,490 | \$ 74,615 |

Expenses recognized under operating leases were as follows:

| | Years Ended December 31 | |
|------------------------|-------------------------|-----------|
| | 2018 | 2017 |
| Minimum lease payments | \$ 38,603 | \$ 42,857 |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(23) Summary statement of employee benefits, depreciation and amortization expenses by function:

| Function Nature | Years Ended December 31 | | | | | |
|---------------------------------|-------------------------|--------------------|---------|-----------------|--------------------|---------|
| | 2018 | | | 2017 | | |
| | Operating costs | Operating expenses | Total | Operating costs | Operating expenses | Total |
| Employee benefits expense | | | | | | |
| Salaries | 449,960 | 440,003 | 889,963 | 466,006 | 417,681 | 883,687 |
| Labor and health insurance | 45,197 | 28,222 | 73,419 | 42,176 | 27,232 | 69,408 |
| Pension | 22,052 | 16,933 | 38,985 | 21,871 | 22,842 | 44,713 |
| Remuneration to directors | - | 20,127 | 20,127 | - | 20,892 | 20,892 |
| Other employee benefits expense | 50,455 | 37,972 | 88,427 | 53,396 | 33,689 | 87,085 |
| Depreciation | 277,404 | 14,058 | 291,462 | 256,844 | 16,856 | 273,700 |
| Amortization | 11,214 | 17,601 | 28,815 | 13,397 | 14,479 | 27,876 |

According to the Company's Articles of Incorporation, when the Company makes a profit for the year, the compensation to employees shall not be lower than five percent of the balance and the remuneration to directors shall not be higher than four percent of the balance. However, if the Company has an accumulated deficit, the profit shall cover the deficit before it can be used for compensation to employees and remuneration to directors. The above-mentioned compensation to employees can be made in the form of stock or cash by a resolution adopted by a majority vote at a Board of Directors' meeting attended by two-thirds of the total number of directors. A report of such distribution shall be submitted to the shareholders' meeting. Information on the compensation to employees and remuneration to directors resolved or reported at the meetings of Board of Directors and shareholders is available at the Market Observation Post System website.

If the Board of Directors resolved to distribute compensation to employees in the form of stock, the closing price of stocks on the date preceding the resolution shall be the basis in calculating the number of stocks to be distributed. If the amount accrued differed from the amount resolved in the Board of Directors' meeting, the difference would be recognized in the profit or loss of the following year.

Information on 2018 compensation to employees and remuneration to directors resolved in the Board of Directors' meeting on January 18, 2019 and 2017 compensation to employees and remuneration to directors reported in the shareholders' meeting on May 29, 2018 was as follows:

| | Years Ended December 31 | |
|---------------------------|-------------------------|-----------|
| | 2018 | 2017 |
| Compensation to employees | \$ 72,535 | \$ 74,579 |
| Remuneration to directors | 19,834 | 20,393 |

The above-mentioned 2017 compensation to employees and remuneration to directors reported in the shareholders' meetings were consistent with the amounts resolved in the Board of Directors' meetings held on January 17, 2018, and the amounts recognized as expenses in the financial statements.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(24) Non-operating income and expenses

A. Other income

| | Years Ended December 31 | |
|-----------------|-------------------------|------------------|
| | 2018 | 2017 |
| Interest income | \$ 20,534 | \$ 17,731 |
| Other income | 20,294 | 9,384 |
| Total | <u>\$ 40,828</u> | <u>\$ 27,115</u> |

B. Other gains and losses

| | Years Ended December 31 | |
|---|-------------------------|-----------------|
| | 2018 | 2017 |
| Gain (loss) on disposal of property, plant and equipment | \$ 856 | \$ (418) |
| Gain on liquidation of subsidiaries | 35,761 | - |
| Foreign exchange (loss) gain, net | (51,256) | 53,774 |
| Gain on reversal of impairment loss for non-financial assets | 31,518 | - |
| Gain (loss) of financial assets (liabilities) at fair value through profit or loss, net | 7,215 | (41,821) |
| Disaster loss (Note 10) | (131,537) | - |
| Other losses | (3,885) | (2,257) |
| Total | <u>\$ (111,328)</u> | <u>\$ 9,278</u> |

C. Finance costs

| | Years Ended December 31 | |
|-----------------------------------|-------------------------|--------------------|
| | 2018 | 2017 |
| Interest on borrowings from banks | \$ (49,248) | \$ (66,046) |
| Interest on finance leases | (341) | (139) |
| Total | <u>\$ (49,589)</u> | <u>\$ (66,185)</u> |

D. Components of other comprehensive income

For the year ended December 31, 2018

| | Arising during the period | Reclassification adjustments during the period | Other comprehensive income | Income tax benefit (expense) | Other comprehensive income, net of tax |
|---|---------------------------|--|----------------------------|------------------------------|--|
| Items that will not be reclassified subsequently to profit or loss: | | | | | |
| Remeasurement of defined benefit plan | \$ 55,488 | \$ — | \$ 55,488 | \$ (11,098) | \$ 44,390 |
| Items that may be reclassified subsequently to profit or loss: | | | | | |
| Exchange differences arising on translation of foreign operations | (86,077) | — | (86,077) | 19,368 | (66,709) |
| Total | <u>\$ (30,589)</u> | <u>\$ —</u> | <u>\$ (30,589)</u> | <u>\$ 8,270</u> | <u>\$ (22,319)</u> |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

For the year ended December 31, 2017

| | Arising during the period | Reclassification adjustments during the period | Other comprehensive income | Income tax benefit (expense) | Other comprehensive income, net of tax |
|--|---------------------------------|---|----------------------------------|------------------------------------|---|
| Items that will not be reclassified subsequently to profit or loss: | | | | | |
| Remeasurement of defined benefit plan | \$ 24,130 | \$ — | \$ 24,130 | \$ (4,102) | \$ 20,028 |
| Items that may be reclassified subsequently to profit or loss: | | | | | |
| Exchange differences arising on translation of foreign operations | (22,115) | — | (22,115) | 3,760 | (18,355) |
| Total | <u>\$ 2,015</u> | <u>\$ —</u> | <u>\$ 2,015</u> | <u>\$ (342)</u> | <u>\$ 1,673</u> |

(25) Income tax

Based on the amendments to the Income Tax Act announced on February 7, 2018, the Company's corporate income tax rate for the year ended December 31, 2018 was adjusted from 17% to 20%. The tax rate applicable to undistributed earnings for the year ended December 31, 2018 was reduced from 10% to 5%.

A. The major components of income tax expense were as follows:

Income tax recognized in profit or loss

| | Years Ended December 31 | |
|--|-------------------------|-------------------|
| | 2018 | 2017 |
| Current income tax expense (benefit): | | |
| Current income tax expense | \$ 255,134 | \$ 178,823 |
| Income tax adjustments on prior years | (3,149) | 18,364 |
| Effect of exchange rate changes | (204) | (621) |
| Deferred income tax expense: | | |
| Income tax expense (benefit) relating to origination and reversal of temporary differences | (77,278) | 15,987 |
| Deferred income tax relating to changes in tax rates | 14,565 | - |
| Total income tax expense | <u>\$ 189,068</u> | <u>\$ 212,553</u> |

Income tax recognized in other comprehensive income

| | Years Ended December 31 | |
|--|-------------------------|---------------|
| | 2018 | 2017 |
| Deferred income tax expense (benefit): | | |
| Remeasurement of defined benefit plan | \$ 11,098 | \$ 4,102 |
| Exchange differences arising on translation of foreign operations | (19,368) | (3,760) |
| Income tax relating to components of other comprehensive income | <u>\$ (8,270)</u> | <u>\$ 342</u> |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

- B. The reconciliation of income tax expense and income tax based on pre-tax net income at the statutory tax rate was as follows

| | Years Ended December 31 | |
|---|-------------------------|------------|
| | 2018 | 2017 |
| Income before tax of continuing operations | \$ 868,542 | \$ 959,098 |
| Income tax expense at the statutory rate of the parent company | \$ 173,708 | \$ 163,047 |
| Additional 10% income tax on unappropriated earnings | 15,836 | 4,963 |
| Tax effects of entities at different tax jurisdictions with different tax rates | (13,580) | 27,352 |
| Income tax adjustments on prior years | (3,149) | 18,364 |
| Tax effects of other tax adjustments | 16,253 | (1,173) |
| Income tax expense recognized in profit or loss | \$ 189,068 | \$ 212,553 |

- C. Balance of deferred income tax assets (liabilities):

For the year ended December 31, 2018

| | Beginning balance | Recognized in profit or loss | Recognized in other comprehensive income | Recognized in equity | Ending balance |
|---|-------------------|------------------------------|--|----------------------|----------------|
| Temporary differences | | | | | |
| Exchange gain and loss | \$ 4,424 | \$ 8,359 | \$ — | \$ — | \$ 12,783 |
| Allowance for inventory valuation and obsolescence loss | 20,458 | 4,224 | — | — | 24,682 |
| Investments accounted for under the equity method | (135,758) | 24,453 | 19,368 | (1,742) | (93,679) |
| Unrealized intra-group profits and losses | 3,667 | 3,840 | — | — | 7,507 |
| Impairment of assets | 10,613 | (5,160) | — | — | 5,453 |
| Allowance for doubtful accounts | 22,442 | (8,212) | — | — | 14,230 |
| Net defined benefit liabilities | 31,301 | 7,481 | (11,098) | — | 27,684 |
| Others | (2,777) | 30,487 | — | — | 27,710 |
| Deferred income tax expense | | \$ 65,472 | \$ 8,270 | \$ (1,742) | |
| Net deferred income tax assets (liabilities) | \$ (45,630) | | | | \$ 26,370 |
| Reflected in balance sheet as follows: | | | | | |
| Deferred income tax assets | \$ 130,697 | | | | \$ 157,314 |
| Deferred income tax liabilities | \$ 176,327 | | | | \$ 130,944 |

For the year ended December 31, 2017

| | Beginning balance | Recognized in profit or loss | Recognized in other comprehensive income | Recognized in equity | Ending balance |
|------------------------|-------------------|------------------------------|--|----------------------|----------------|
| Temporary differences | | | | | |
| Exchange gain and loss | \$ 5,078 | \$ (654) | \$ — | \$ — | \$ 4,424 |

(Continued)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

| | Beginning balance | Recognized in profit or loss | Recognized in other comprehensive income | Recognized in equity | Ending balance |
|---|----------------------|---------------------------------|---|-------------------------|--------------------|
| Allowance for inventory valuation and obsolescence loss | \$ 10,057 | \$ 10,401 | \$ — | \$ — | \$ 20,458 |
| Investments accounted for under the equity method | (125,958) | (13,560) | 3,760 | — | (135,758) |
| Unrealized intra-group profits and losses | 8,766 | (5,099) | — | — | 3,667 |
| Impairment of assets | 12,549 | (1,936) | — | — | 10,613 |
| Allowance for doubtful accounts | 34,295 | (11,853) | — | — | 22,442 |
| Net defined benefit liabilities | 32,347 | 3,056 | (4,102) | — | 31,301 |
| Others | (6,424) | 3,647 | — | — | (2,777) |
| Deferred income tax expense | | <u>\$ (15,998)</u> | <u>\$ (342)</u> | <u>\$ —</u> | |
| Net deferred income tax assets (liabilities) | <u>\$ (29,290)</u> | | | | <u>\$ (45,630)</u> |
| Reflected in balance sheet as follows: | | | | | |
| Deferred income tax assets | <u>\$ 129,825</u> | | | | <u>\$ 130,697</u> |
| Deferred income tax liabilities | <u>\$ 159,115</u> | | | | <u>\$ 176,327</u> |
| | | | | | (Concluded) |

D. Unrecognized deferred income tax assets:

As of December 31, 2018 and 2017, deferred income tax assets that had not been recognized by the Group amounted to NT\$42,371 thousand and NT\$45,008 thousand, respectively.

E. The assessment of income tax returns:

As of December 31, 2018, the income tax return assessments of the Group's entities in ROC were as follows:

| | <u>The assessment of income tax returns</u> |
|--|---|
| The Company | Assessed and approved up to 2016 |
| Subsidiary- Koatech Technology Corporation | Assessed and approved up to 2016 |

(26) Earnings per share

| | <u>Year Ended December 31, 2018</u> | | |
|--|-------------------------------------|---|-------------------|
| | <u>Amount after-tax</u> | <u>Weighted average number of outstanding shares (in thousands)</u> | <u>EPS (NT\$)</u> |
| <u>Basic earnings per share</u> | | | |
| Net income available to common shareholders of the Company | \$ 672,309 | 209,084 | <u>\$ 3.22</u> |
| Effect of dilutive potential common stocks | | | |
| Employee compensation - stock | — | 2,142 | |
| <u>Diluted earnings per share</u> | | | |
| Net income available to common shareholders of the Company and effect of potential common stocks | <u>\$ 672,309</u> | <u>211,226</u> | <u>\$ 3.18</u> |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

| | Year Ended December 31, 2017 | | |
|--|------------------------------|---|----------------|
| | Amount after-tax | Weighted average number of outstanding shares (in thousands) | EPS (NT\$) |
| <u>Basic earnings per share</u> | | | |
| Net income available to common shareholders of the Company | \$ 734,589 | 206,938 | <u>\$ 3.55</u> |
| Effect of dilutive potential common stocks | | | |
| Employee compensation - stock | — | 1,406 | |
| <u>Diluted earnings per share</u> | | | |
| Net income available to common shareholders of the Company and effect of potential common stocks | <u>\$ 734,589</u> | <u>208,344</u> | <u>\$ 3.53</u> |

7. Related Party Transactions

(1) Names and relationships

| Name | Relationship |
|-------------------------------|--|
| Innatech Co., Ltd. (Innatech) | Its chairperson is the Company's chairperson |

(2) Significant transactions with related parties

A. Other payables – related parties

| | December 31, 2018 | December 31, 2017 |
|-----------------------|----------------------|----------------------|
| Other related parties | <u>\$ 648</u> | <u>\$ 441</u> |

B. Compensation to key management of the Group

| | Years Ended December 31 | |
|------------------------------|-------------------------|------------------|
| | 2018 | 2017 |
| Short-term employee benefits | \$ 73,939 | \$ 72,798 |
| Post-employment benefits | 641 | 6,396 |
| Termination benefits | 783 | - |
| Total | <u>\$ 75,363</u> | <u>\$ 79,194</u> |

8. Pledged Assets

The following table listed assets of the Group pledged as collateral:

| | Carrying Amount | | Purpose of Pledge |
|-------------------------|----------------------|----------------------|---|
| | December 31, 2018 | December 31, 2017 | |
| Time deposits (Note) | \$ 20,413 | \$ 20,354 | Customs guarantee |
| Land | 100,843 | 100,843 | Long-term loans |
| Buildings | 100,749 | 104,185 | Letter of credit, short-term credit facilities and long-term loans |
| Machinery and equipment | 12,513 | 14,163 | Long-term loans |
| Total | <u>\$ 234,518</u> | <u>\$ 239,545</u> | |

Note: Those assets were recognized as other current assets – other.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

9. Significant Contingencies and Unrecognized Contract Commitments

Details of the Group's unused letters of credit as of December 31, 2018 were as follows:

| | L / C Balance | |
|-----|---------------|------------------|
| NTD | NT\$ | 12,501 thousand |
| USD | US\$ | 6,974 thousand |
| JPY | JPY | 384,960 thousand |

10. Significant Disaster Loss

A fire broke out in the Group's subsidiary, Taiflex Scientific (Kunshan) Co., Ltd., on January 25, 2018. Parts of the plants, equipment and inventories were damaged, flooded and suffered from smoke and dust pollution. The repair and cleaning work were still underway. Those assets were covered by fire insurance policies. As of December 31, 2018, the insurance claim was still being processed by the insurance company.

11. Significant Subsequent Events

None.

12. Others

(1) Categories of financial instruments

Financial assets

| | December 31, 2018 | December 31, 2017 |
|--|----------------------|----------------------|
| Financial assets at fair value through profit or loss: | | |
| Held for trading | (Note 1) | \$ 17,463 |
| Mandatorily at fair value through profit or loss | \$ 36,438 | (Note 1) |
| Financial assets at amortized cost: | | |
| Cash and cash equivalents (excluding cash on hand) | 1,861,898 | (Note 1) |
| Receivables | 4,950,722 | (Note 1) |
| Other financial assets - current | 20,413 | (Note 1) |
| Loans and receivables (Note 2) | (Note 1) | 6,786,254 |

Financial liabilities

| | December 31, 2018 | December 31, 2017 |
|---|----------------------|----------------------|
| Financial liabilities at fair value through profit or loss: | | |
| Held for trading | \$ — | \$ 13,351 |
| Financial liabilities at amortized cost: | | |
| Short-term loans | 1,362,054 | 656,596 |
| Payables | 2,378,788 | 3,083,571 |
| Long-term loans (including current portion) | 341,932 | 255,696 |

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

Note: 1. The Group adopted IFRS 9 on January 1, 2018 and chose not to restate the comparative periods in accordance with the transitional provisions of IFRS 9.

2. Including cash and cash equivalents, notes and accounts receivables, other receivables and other financial assets – current.

(2) Objectives of financial risk management

The Group's principal financial risk management objective is to manage the market risk, credit risk and liquidity risk related to its operating activities. The Group identifies, measures, and manages the aforementioned risks based on its policy and risk preferences.

The Group has established appropriate policies, procedures and internal controls for the aforementioned financial risk management. Before entering into significant transactions, due approval process by the Board of Directors must be carried out based on related protocols and internal control procedures. The Group shall comply with its financial risk management policies at all times.

(3) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of the changes in market prices. Market risk comprises foreign currency risk, interest rate risk and other price risks.

In practice, it is rarely the case that a single risk variable will change independently from other risk variables. There are usually interdependencies between risk variables. However, the sensitivity analysis disclosed below does not take into account the interdependencies between risk variables.

A. Foreign currency risk

The Group's exposure to foreign currency risk relates primarily to its operating activities (when revenue or expense are denominated in a different currency from the Group's functional currency) and net investments in foreign operations.

The Group has certain foreign currency receivables denominated in the same foreign currency as certain foreign currency payables, therefore natural hedge is achieved. The Group also uses forward contracts to hedge the foreign currency risk on certain items denominated in foreign currencies. Hedge accounting is not applied as the said nature hedge and forward contracts do not qualify for hedge accounting criteria. Furthermore, as net investments in foreign operations are for strategic purposes, they are not hedged by the Group.

The foreign currency sensitivity analysis of the impact of possible changes in foreign exchange rates on the Group's profit and equity is performed on significant monetary items denominated in foreign currencies as of the end of the reporting period. The Group's foreign currency risk is mainly related to the volatility in the exchange rates of U.S. dollars and Chinese Yuan.

B. Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to interest rate risk relates primarily to its variable interest rates for loans.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

The Group manages its interest rate risk by having a balanced portfolio of fixed and variable rate loans.

C. Equity price risk

Equity securities of listed domestic companies held by the Group are susceptible to market price risk arising from uncertainties about future values of the investment securities. The Group manages the equity price risk through diversification and placing limits on individual and total equity instruments. Reports on equity portfolio are submitted to the Group's senior management on a regular basis. The Board of Directors shall review all equity investment decisions and approve where appropriate.

A 5% increase/decrease in the prices of listed companies' stocks classified as mandatorily at fair value through profit or loss (held for trading in 2017) could cause the profit or loss for the years ended December 31, 2018 and 2017 to increase/decrease by NT\$1,021 thousand and NT\$834 thousand, respectively.

D. Information on the pre-tax sensitivity analysis was as follows:

For the year ended December 31, 2018

| Key Risk | Variation | Sensitivity of Profit or Loss |
|-----------------------|---|-------------------------------|
| Foreign currency risk | NTD/USD appreciate/depreciate by 1% | -/+ NT\$21,480 thousand |
| | NTD/CNY appreciate/depreciate by 1% | -/+ NT\$ 202 thousand |
| Interest rate risk | Market interest rate increase/decrease by 10 basis points | +/- NT\$ 159 thousand |

For the year ended December 31, 2017

| Key Risk | Variation | Sensitivity of Profit or Loss |
|-----------------------|---|-------------------------------|
| Foreign currency risk | NTD/USD appreciate/depreciate by 1% | -/+ NT\$ 5,120 thousand |
| | NTD/CNY appreciate/depreciate by 1% | -/+ NT\$ 1,741 thousand |
| Interest rate risk | Market interest rate increase/decrease by 10 basis points | +/- NT\$ 1,022 thousand |

(4) Credit risk management

Credit risk is the risk that counterparty will not meet its obligations under a contract and result in a financial loss. The Group is exposed to credit risk from operating activities (primarily for accounts and notes receivable) and financing activities (primarily for bank deposits and various financial instruments).

Credit risk is managed by each business unit subject to the Group's credit risk policies, procedures and controls. Credit risk of all counterparties is assessed by considering their financial position, rating from credit rating agencies, past experience, current economic environment and the Group's internal rating criteria, etc. Certain customer's credit risk will also be managed by using credit enhancement tools, such as prepayments or insurances, to reduce their credit risk.

Credit risk from balances with banks and other financial instruments is managed by the Group's finance division in accordance with the Group's policies. The counterparties that the Group transacts with are reputable financial institutions both at home and abroad, thus, no significant credit risk is expected.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(5) Liquidity risk management

The Group maintains its financial flexibility through the use of cash and cash equivalents and bank borrowings. The table below summarized the maturity profile of the Group's financial liability contracts based on the earliest repayment dates and contractual undiscounted cash flows. The amount included the contractual interest. The undiscounted interest payment relating to borrowings with variable interest rates was extrapolated based on the yield curve as of the end of the reporting period.

Non-derivative financial liabilities

| | Less than 1 year | 2 to 3 years | 4 to 5 years | > 5 years | Total |
|--------------------------|------------------|--------------|--------------|-----------|--------------|
| <u>December 31, 2018</u> | | | | | |
| Borrowings | \$ 1,375,895 | \$ 295,000 | \$ 34,674 | \$ — | \$ 1,705,569 |
| Payables | 2,378,788 | — | — | — | 2,378,788 |
| <u>December 31, 2017</u> | | | | | |
| Borrowings | \$ 703,908 | \$ 165,291 | \$ 45,580 | \$ — | \$ 914,779 |
| Payables | 3,083,571 | — | — | — | 3,083,571 |

Derivative financial liabilities

| | Less than 1 year | 2 to 3 years | 4 to 5 years | > 5 years | Total |
|--------------------------|------------------|--------------|--------------|-----------|--------------|
| <u>December 31, 2018</u> | | | | | |
| Inflows | \$ 526,637 | \$ — | \$ — | \$ — | \$ 526,637 |
| Outflows | \$ 605,689 | — | — | — | \$ 605,689 |
| Net | \$ (79,052) | \$ — | \$ — | \$ — | \$ (79,052) |
| <u>December 31, 2017</u> | | | | | |
| Inflows | \$ 1,058,336 | \$ — | \$ — | \$ — | \$ 1,058,336 |
| Outflows | \$ 1,079,765 | — | — | — | \$ 1,079,765 |
| Net | \$ (21,429) | \$ — | \$ — | \$ — | \$ (21,429) |

The derivative financial liabilities in the table above were expressed using undiscounted net cash flows.

(6) Reconciliation of liabilities arising from financing activities

Reconciliation of liabilities for the year ended December 31, 2018:

| | Short-term Loan | Long-term Loan | Lease Liability | Total Liabilities from Financing Activities |
|-------------------------|--------------------|-------------------|--------------------|---|
| As of January 1, 2018 | \$ 656,596 | \$ 255,696 | \$ 3,138 | \$ 915,430 |
| Cash flows | 705,458 | 86,236 | (1,036) | 790,658 |
| Non-cash movement | — | — | 341 | 341 |
| As of December 31, 2018 | <u>\$1,362,054</u> | <u>\$ 341,932</u> | <u>\$ 2,443</u> | <u>\$1,706,429</u> |

Reconciliation of liabilities for the year ended December 31, 2017: Not applicable.

(7) Fair values of financial instruments

A. The methods and assumptions applied in determining the fair value of financial instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

following methods and assumptions are used by the Group in measuring or disclosing the fair values of financial assets and liabilities:

- (a) The carrying amount of cash and cash equivalents, receivables, payables and other current liabilities approximate their fair value due to short maturity terms.
- (b) For financial assets and liabilities traded in an active market with standard terms and conditions, their fair value is determined based on market quotation price (e.g. listed equity securities, beneficiary certificates, bonds and futures).

B. Fair value of financial instruments measured at amortized cost

The carrying amount of the Group's financial assets and liabilities measure at amortized cost approximates their fair value.

C. Information on the fair value hierarchy of financial instruments

Please refer to Note 12(9) for details.

(8) Derivative instruments

As of December 31, 2018 and 2017, the Group's derivative instruments that were not eligible for hedge accounting and were outstanding were listed as follows:

A. Forward foreign exchange contracts that were not eligible for hedge accounting and were outstanding as of the balance sheet date were listed as follows:

| Currency | Contract Period | Contract Amount (in thousands) |
|--------------------------|-----------------|-----------------------------------|
| <u>December 31, 2018</u> | | |
| Sell CNY/Buy USD | 2018.03~2019.07 | CNY 60,939/US\$ 9,300 |
| Sell CNY/Buy NTD | 2018.11~2019.05 | CNY 90,000/NT\$ 396,597 |
| Sell USD/Buy NTD | 2018.12~2019.03 | US\$ 6,000/NT\$ 183,577 |
| <u>December 31, 2017</u> | | |
| Sell CNY/Buy USD | 2017.05~2018.04 | CNY 82,813/US\$ 12,342 |
| Sell CNY/Buy NTD | 2017.09~2018.04 | CNY 126,000/NT\$ 566,937 |

B. Foreign exchange swap contracts that were not eligible for hedge accounting and were outstanding as of the balance sheet date were listed as follows:

| Currency | Contract Period | Contract Amount (in thousands) |
|--------------------------|-----------------|-----------------------------------|
| <u>December 31, 2018</u> | | |
| Sell CNY/Buy NTD | 2018.08~2019.04 | CNY 4,200/NT\$ 18,463 |
| <u>December 31, 2017</u> | | |
| Sell CNY/Buy NTD | 2017.09~2018.04 | CNY 4,200/NT\$ 18,822 |

C. Cross-currency swap contracts that were not eligible for hedge accounting and were outstanding as of the balance sheet date were listed as follows:

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

| Currency | Contract Period | Contract Amount (in thousands) | Range of Interest Rate Paid | Range of Interest Rate Received |
|--------------------------|-----------------|-----------------------------------|--------------------------------|------------------------------------|
| <u>December 31, 2018</u> | | | | |
| Sell CNY/Buy USD | 2018.01~2019.01 | CNY 12,870/ US\$ 2,000 | 2.82%~4.10% | 1.70%~2.81% |
| <u>December 31, 2017</u> | | | | |
| Sell CNY/Buy USD | 2017.09~2018.11 | CNY 23,027/ US\$ 3,500 | 2.82%~3.65% | 1.70%~1.80% |

For forward foreign exchange, foreign exchange swap and cross-currency swap contracts, the main purpose is to hedge the foreign currency risk of net assets or liabilities denominated in foreign currencies. As there will be corresponding cash inflows or outflows upon expiration and the Company has sufficient operation funds, no significant cash flow risk is expected.

(9) Fair value hierarchy

A. Definition of fair value hierarchy

For assets and liabilities measured or disclosed in fair values, they are categorized in the level of the lowest level input that is significant to the entire measurement. Inputs of each level are as follows:

Level 1 inputs are quoted (unadjusted) prices in active markets for identical assets or liabilities at the measurement date

Level 2 inputs are inputs other than quoted market prices included within level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 inputs are unobservable inputs for the asset or liability

For assets and liabilities measured at a recurring basis, their categories shall be re-evaluated at the end of each reporting period to determine if there is any transfer between different levels of fair value hierarchy.

B. Hierarchy of fair value measurement

The Group does not have assets that are measured at fair value on a non-recurring basis. The fair value hierarchy of assets and liabilities measured at a recurring basis was disclosed as follows:

| | Level 1 | Level 2 | Level 3 | Total |
|---|---------|-----------|---------|-----------|
| <u>December 31, 2018</u> | | | | |
| Financial assets: | | | | |
| Financial assets at fair value through profit or loss | | | | |
| Forward foreign exchange contracts | \$ — | \$ 13,659 | \$ — | \$ 13,659 |
| Cross-currency swap contracts | — | 2,358 | — | 2,358 |
| Stocks | 20,421 | — | — | 20,421 |

(Continued)

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

| | Level 1 | Level 2 | Level 3 | Total |
|---|---------|----------|---------|----------|
| Financial liabilities: | | | | |
| Financial liabilities at fair value through profit or loss | | | | |
| Forward foreign exchange contracts | \$ — | \$ 2,471 | \$ — | \$ 2,471 |
| Foreign exchange swap contracts | — | 185 | — | 185 |
| | | | | |
| <u>December 31, 2017</u> | | | | |
| Financial assets: | | | | |
| Financial assets at fair value through profit or loss | | | | |
| Forward foreign exchange contracts | \$ — | \$ 214 | \$ — | \$ 214 |
| Cross-currency swap contracts | — | 572 | — | 572 |
| Stocks | 16,677 | — | — | 16,677 |
| | | | | |
| Financial liabilities: | | | | |
| Financial liabilities at fair value through profit or loss | | | | |
| Forward foreign exchange contracts | — | 13,058 | — | 13,058 |
| Foreign exchange swap contracts | — | 224 | — | 224 |
| Cross-currency swap contracts | — | 69 | — | 69 |

(Concluded)

For the years ended December 31, 2018 and 2017, there were no transfers between Level 1 and Level 2 fair value hierarchy.

(10) Significant financial assets and liabilities denominated in foreign currencies

Information regarding significant financial assets and liabilities denominated in foreign currencies was listed below:

| | December 31, 2018 | | | December 31, 2017 | | |
|------------------------------|--------------------------------------|---------------|--------------|--------------------------------------|---------------|--------------|
| | Foreign Currencies (in thousands) | Exchange Rate | NTD | Foreign Currencies (in thousands) | Exchange Rate | NTD |
| <u>Financial assets</u> | | | | | | |
| <u>Monetary items</u> | | | | | | |
| USD | \$ 115,349 | 30.7220 | \$ 3,543,738 | \$ 83,788 | 29.8300 | \$ 2,499,396 |
| CNY | 4,640 | 4.4730 | 20,754 | 38,906 | 4.5745 | 177,975 |
| | | | | | | |
| <u>Financial liabilities</u> | | | | | | |
| <u>Monetary items</u> | | | | | | |
| USD | \$ 45,429 | 30.7220 | \$ 1,395,662 | \$ 66,607 | 29.8300 | \$ 1,986,887 |
| JPY | 192,735 | 0.2781 | 53,600 | 224,995 | 0.2648 | 59,579 |

The data above was disclosed based on the carrying amounts in foreign currencies (already translated to functional currencies).

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

As entities within the Group transact in various currencies, the exchange gain (loss) of monetary financial assets and liabilities cannot be disclosed by currencies of significant influence. For the years ended December 31, 2018 and 2017, the Group's foreign exchange gain (loss) amounted to NT\$(51,256) thousand and NT\$53,774 thousand, respectively.

(11) Capital management

The primary objective of the Group's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and maximize shareholder value. The Group manages and adjusts its capital structure in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust dividend payment to shareholders, return capital to shareholders or issue new shares.

13. Additional Disclosures

(1) Information on significant transactions and investees

- A. Financing provided to others: Please refer to Table 1.
- B. Endorsement/Guarantee provided to others: Please refer to Table 2.
- C. Marketable securities held as of December 31, 2018 (excluding investments in subsidiaries, associates and joint ventures): Please refer to Table 3.
- D. Individual securities acquired or disposed of with accumulated amount of at least NT\$300 million or 20 percent of the paid-in capital for the year ended December 31, 2018: None.
- E. Acquisition of individual real estate with amount of at least NT\$300 million or 20 percent of the paid-in capital for the year ended December 31, 2018: None.
- F. Disposal of individual real estate with amount of at least NT\$300 million or 20 percent of the paid-in capital for the year ended December 31, 2018: None.
- G. Related party transactions with purchase or sales amount of at least NT\$100 million or 20 percent of the paid-in capital for the year ended December 31, 2018: Please refer to Table 4.
- H. Receivables from related parties of at least NT\$100 million or 20 percent of the paid-in capital as of December 31, 2018: Please refer to Table 5.
- I. Direct or indirect significant influence or control over the investees for the year ended December 31, 2018 (excluding investments in China): Please refer to Table 6.
- J. Derivative financial instruments transactions: Please refer to Note 12.
- K. Others: intercompany relationships and significant intercompany transactions for the year ended December 31, 2018: Please refer to Table 8.

(2) Information on investments in Mainland China: Please refer to Table 7.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

14. Operating Segment Information

For management purposes, the Group is organized into operating segments based on each independent utility. The two reportable operating segments are as follows:

The general management segment is responsible for the Group's operation planning and owns manufacturing, R&D and sales functions.

The overseas segment owns manufacturing and sales functions.

Operating segments have not been aggregated to form the above reportable operating segments.

Management monitors the operating results of its business units separately for the purpose of decision-making on resource allocation and performance assessment. Segment performance is evaluated based on operating profit or loss and measured consistently with methods applied to operating profit or loss in the consolidated financial statements. However, finance costs, financial benefits and income taxes are managed on the Group basis and are not allocated to operating segments.

(1) Segment income (loss)

For the year ended December 31, 2018

| | General Management | Overseas | Adjustment and Elimination (Note) | Consolidated |
|---|-----------------------|---------------------|---|---------------------|
| Revenue | | | | |
| External customer | \$ 5,628,299 | \$ 4,014,752 | \$ — | \$ 9,643,051 |
| Inter-segment | 2,265,220 | 152,532 | (2,417,752) | — |
| Total revenue | <u>\$ 7,893,519</u> | <u>\$ 4,167,284</u> | <u>\$ (2,417,752)</u> | <u>\$ 9,643,051</u> |
| Segment income (loss) (before income tax) | <u>\$ 886,242</u> | <u>\$ 267,651</u> | <u>\$ (285,351)</u> | <u>\$ 868,542</u> |

Note: Inter-segment revenues were eliminated upon consolidation.

For the year ended December 31, 2017

| | General Management | Overseas | Adjustment and Elimination (Note) | Consolidated |
|---|-----------------------|---------------------|---|----------------------|
| Revenue | | | | |
| External customer | \$ 5,180,790 | \$ 6,012,102 | \$ — | \$ 11,192,892 |
| Inter-segment | 2,462,441 | 225,279 | (2,687,720) | — |
| Total revenue | <u>\$ 7,643,231</u> | <u>\$ 6,237,381</u> | <u>\$ (2,687,720)</u> | <u>\$ 11,192,892</u> |
| Segment income (loss) (before income tax) | <u>\$ 929,726</u> | <u>\$ 195,496</u> | <u>\$ (166,124)</u> | <u>\$ 959,098</u> |

Note: Inter-segment revenues were eliminated upon consolidation.

TAIFLEX SCIENTIFIC COMPANY LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
(In Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(2) Geographic information

A. Revenue from external customers:

| Region | Years Ended December 31 | |
|----------------|-------------------------|----------------------|
| | 2018 | 2017 |
| Taiwan | \$ 1,931,443 | \$ 2,108,157 |
| Mainland China | 7,364,249 | 8,713,945 |
| Others | 347,359 | 370,790 |
| Total | <u>\$ 9,643,051</u> | <u>\$ 11,192,892</u> |

Revenue was categorized based on countries where customers are located.

B. Non-current assets:

| Region | Years Ended December 31 | |
|----------------|-------------------------|---------------------|
| | 2018 | 2017 |
| Taiwan | \$ 2,617,315 | \$ 2,503,588 |
| Mainland China | 899,516 | 696,971 |
| Total | <u>\$ 3,516,831</u> | <u>\$ 3,200,559</u> |

(3) Major customers

Customers accounted for at least 10% of the Group's net revenue for the years ended December 31, 2018 and 2017 were as follows:

| Name | Years Ended December 31 | |
|------------|-------------------------|--------------|
| | 2018 | 2017 |
| Customer A | \$ 1,608,965 | \$ 1,550,537 |
| Customer B | 444,675 | 1,181,091 |
| Customer C | 1,161,924 | 1,102,789 |

TABLE 1: FINANCING PROVIDED TO OTHERS

(In Thousands of New Taiwan Dollars)

| No. (Note 1) | Financing Company | Counterparty | Financial Statement Account (Note 2) | Whether A Related Party | Maximum Balance for the Period (Note 3) | Ending Balance (Note 10) | Amount Actually Drawn (Note 11) | Interest Rate Range | Nature of Financing (Note 4) | Transaction Amounts (Note 5) | Reason for Short-term Financing (Note 6) | Loss Allowance | Collateral | | Financing Limits for Each Borrower | Financing Company's Total Financing Amount Limits | Note |
|-----------------|------------------------------|--|--------------------------------------|-------------------------|---|--------------------------|---------------------------------|---------------------|------------------------------|------------------------------|--|----------------|------------|-------|------------------------------------|---|----------|
| | | | | | | | | | | | | | Item | Value | | | |
| 0 | Taiflex Scientific Co., Ltd. | Shenzhen Taiflex Electronic Co., Ltd. | Other receivables - related parties | Y | \$ 433,426 | \$ 430,108 | \$ 276,498 | 1.70%~4.00% | 2 | — | Operating capital | — | — | — | \$ 1,452,448 | \$ 2,904,895 | (Note 7) |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | Other receivables - related parties | Y | 1,229,040 | 921,660 | 721,744 | 1.70%~4.00% | 2 | — | Operating capital | — | — | — | 1,452,448 | 2,904,895 | (Note 7) |

Note 1: Companies are coded as follows:

(1) Taiflex Scientific Co., Ltd. is coded "0".

(2) The investees are coded from "1" in the order presented in the table above.

Note 2: Receivables from affiliates and related parties, shareholder transactions, prepayments and temporary payments, etc. are required to be disclosed in this field if they are financings provided to others.

Note 3: The maximum balance of financing provided to others for the year ended December 31, 2018.

Note 4: Nature of Financing are coded as follows:

(1) Business transaction is coded "1".

(2) Short-term financing is coded "2".

Note 5: If the nature of financing is business transaction, the amount of transaction shall be disclosed. The amount of transaction refers to the business transaction amount of the most recent year between the financing company and the borrower.

Note 6: With respect to short-term financing, the reasons of financing and the purpose of use by the counterparty shall be specified, such as loan repayment, equipment acquisition or operating capital.

Note 7: The Company's "Procedures for Lending Funds to Other Parties" stipulates that the amount of financing provided shall not exceed 40% of the Company's net worth in the most recent financial statements. The amount of financing provided to any single entity shall not exceed 20% of the Company's net worth in the most recent financial statements.

Note 8: Total amount of financing to firms or companies having business relationship with the Company shall not exceed 20% of the Company's net worth. The financing amount to an individual party is limited to the transaction amount between both parties. The transaction amount means the purchasing or sales amount between the parties, whichever is higher, and shall not exceed 10% of the Company's net worth. However, the lending amount to a single enterprise whose voting rights are 100% held, either directly or indirectly, by the Company shall not exceed 20% of the Company's net worth.

Note 9: For subsidiaries that the Company holds, either directly and indirectly, 100% of the voting rights, the financing provided to any single entity shall not exceed 20% of the financing company's net worth in the most recent financial statements. Total financing shall not exceed 40% of the financing company's net worth in the most recent financial statements.

Note 10: If public companies, pursuant to Paragraph 1, Article 14 of Regulations Governing Loaning of Funds and Making of Endorsements / Guarantees by Public Companies, resolve each individual lending at the board meetings, the amounts resolved before drawing shall be the publicly-announced balance to disclose the risk they assume; provided however, if any repayment is made subsequently, the outstanding balance after such repayment shall be disclosed to reflect the risk adjusted. If public companies, pursuant to Paragraph 2, Article 14 of the same Regulations, authorize the chairperson by board resolution, within a certain monetary limit and a period not to exceed one year, to give loans in instalments or to make a revolving credit line available, the amount resolved shall be the publicly-announced balance. Although repayment may be made subsequently, as drawings are likely to happen again, the amount of financing resolved by the board shall be recorded as the publicly-announced balance.

Note 11: This is the ending balance after evaluation.

TABLE 2: ENDORSEMENT/GUARANTEE PROVIDED TO OTHERS

(In Thousands of New Taiwan Dollars)

| No (Note 1) | Endorsement/ Guarantee Provider | Guaranteed Party | | Limits on Endorsement/ Guarantee Amount Provided to Each Guaranteed Party (Note 3) | Maximum Balance for the Period (Note 4) | Ending Balance (Note 5) | Amount Actually Drawn (Note 6) | Amount of Endorsement/ Guarantee Secured by Properties | Ratio of Accumulated Endorsement/ Guarantee to Net Worth per Latest Financial Statements | Maximum Endorsement/ Guarantee Amount Allowed (Note 3) | Endorsement Provided by Parent Company to Subsidiaries (Note 7) | Endorsement Provided by Subsidiaries to Parent Company (Note 7) | Endorsement Provided to Subsidiaries in China (Note 7) |
|----------------|---------------------------------------|---|--------------------------|---|--|-------------------------------|---|--|--|---|--|--|--|
| | | Name | Relationship (Note 2) | | | | | | | | | | |
| 0 | Taiflex Scientific Co., Ltd. | Taistar Co., Ltd. | 2 | \$ 3,631,119 | \$ 123,836 | \$ 122,888 | \$ — | \$ — | 1.69% | \$ 3,631,119 | Y | N | N |
| 0 | Taiflex Scientific Co., Ltd. | Rudong Fuzhan Scientific Co., Ltd. | 2 | 3,631,119 | 139,316 | 138,249 | 94,023 | — | 1.90% | | Y | N | Y |
| 0 | Taiflex Scientific Co., Ltd. | Shenzhen Taiflex Electronic Co., Ltd. | 2 | 3,631,119 | 1,320,872 | 1,214,801 | 57,165 | — | 16.73% | | Y | N | Y |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | 2 | 3,631,119 | 1,088,519 | 441,410 | 61,444 | — | 6.08% | | Y | N | Y |

Note 1: Companies are coded as follows:

(1) Taiflex Scientific Co., Ltd. is coded "0".

(2) The investees are coded from "1" in the order presented in the table above.

Note 2: The relationships between endorsement/guarantee providers and guaranteed parties are categorized into the following seven types. Please specify the type.

(1) A company that has business relationships with Taiflex.

(2) A company in which Taiflex directly or indirectly holds over 50% of the voting rights.

(3) A company that directly or indirectly holds over 50% of Taiflex's voting rights.

(4) Endorsements/guarantees between companies in which Taiflex directly or indirectly holds over 90% of the voting rights.

(5) Mutual endorsements/guarantees between companies in the same industry or between joint builders which are provided in accordance with contractual terms for construction projects.

(6) Endorsements/guarantees provided by each shareholder for their jointly invested company in proportion to their shareholding percentages.

(7) Joint and several securities between companies in the same industry for performance guarantees of pre-construction homes under the Consumer Protection Act.

Note 3: The overall amount of guarantees/endorsements shall not exceed 50% of the Company's net worth in the most recent financial statements. The amount of guarantees/endorsements provided to a single entity shall not exceed 20% of the net worth in the most recent financial statements. However, the restriction does not apply to guarantees/endorsements to companies whose voting rights are 100% held, either directly or indirectly, by the Company.

Note 4: The maximum endorsement/guarantee balance for the year ended December 31, 2018.

Note 5: This refers amounts approved by the board of directors. However, for matters delegated by the board to the chairperson in accordance with Subparagraph 8, Article 12 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies, this would be the amounts approved by the chairperson.

Note 6: This is the ending balance after evaluation.

Note 7: Fill in "Y" for endorsements/guarantees provided by listed parent companies to subsidiaries and vice versa, and for ones provided to subsidiaries in Mainland China.

TABLE 3: MARKETABLE SECURITIES HELD AS OF DECEMBER 31, 2018 (EXCLUDING INVESTMENTS IN SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES)
(In Thousands of New Taiwan Dollars)

| Name of Held Company | Type of Marketable Securities (Note 1) | Name of Marketable Securities (Note 1) | Relationship with the Company (Note 2) | Financial Statement Account | December 31, 2018 | | | | Note |
|------------------------------|--|--|--|---|-----------------------|--------------------------|-------------------------|------------|------|
| | | | | | Shares (In Thousands) | Carrying Amount (Note 3) | Percentage of Ownership | Fair Value | |
| Taiflex Scientific Co., Ltd. | Non-listed (OTC) stocks | Exploit Technology Co., Ltd. | — | Financial assets at fair value through other comprehensive income - non-current | 25 | — | 0.30% | — | — |
| | Non-listed (OTC) stocks | Kyoritsu Optronics Co., Ltd. | — | Financial assets at fair value through other comprehensive income - non-current | 741 | — | 18.10% | — | — |
| | Listed stocks | Zhen Ding Technology Holding Limited | — | Financial assets at fair value through profit or loss - current | 255 | \$ 20,421 | 0.03% | \$ 20,421 | — |

Note 1: The marketable securities stated in this table shall refer to stocks, bonds, beneficiary certificates and securities derived from the said items within the scope of IFRS 9 "Financial Instruments".

Note 2: Not required if the issuer of the marketable securities is not a related party.

Note 3: If measured at fair value, please fill in the carrying amount after valuation adjustment of fair value and net of accumulated impairment. If not measured at fair value, please fill in the original cost or the carrying value of amortized cost, net of accumulated impairment.

TABLE 4: RELATED PARTY TRANSACTIONS WITH PURCHASE OR SALES AMOUNT OF AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL
(In Thousands of New Taiwan Dollars)

| Company Name | Related Party | Relationships | Transaction Details | | | | Abnormal Transaction (Note 1) | | Notes/Accounts Receivable (Payable) | | Note |
|--|--|---|---------------------|------------|---------------------------------------|----------------------------|-------------------------------|-----------------------|-------------------------------------|--|------|
| | | | Sales (Purchases) | Amount | Percentage to Total Sales (Purchases) | Credit/ Payment Terms | Unit Price | Credit/ Payment Terms | Ending Balance | Percentage to Total Notes/ Accounts Receivable (Payable) | |
| Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | Holds 100% of the third-tier subsidiary | Purchases | \$ 109,900 | 2.15% | 150 days from end of month | — | — | \$ (24,716) | (1.50%) | — |
| | Shenzhen Taiflex Electronic Co., Ltd. | Holds 100% of the third-tier subsidiary | Sales | 2,096,373 | 27.46% | 150 days from end of month | — | — | 1,318,944 | 38.44% | — |
| Taiflex Scientific (Kunshan) Co., Ltd. | Taiflex Scientific Co., Ltd. | The company's ultimate parent company | Sales | 109,900 | 7.79% | 150 days from end of month | — | — | 24,716 | 2.43% | — |
| Shenzhen Taiflex Electronic Co., Ltd. | Taiflex Scientific Co., Ltd. | The company's ultimate parent company | Purchases | 2,096,373 | 68.63% | 150 days from end of month | — | — | (1,318,944) | (85.12%) | — |

Note 1: The sales prices and collection terms to related parties are not significantly different from those of sales to non-related parties.

TABLE 5: RECEIVABLES FROM RELATED PARTIES OF AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL
(In Thousands of New Taiwan Dollars)

| Company Name | Related Party | Relationships | Ending Balance | Turnover Ratio (times) | Overdue | | Amounts Received in Subsequent Periods | Lost Allowance | Note |
|------------------------------|---------------------------------------|---|----------------|------------------------|---------|--------------|--|----------------|------|
| | | | | | Amount | Action Taken | | | |
| Taiflex Scientific Co., Ltd. | Shenzhen Taiflex Electronic Co., Ltd. | Holds 100% of the third-tier subsidiary | \$ 1,318,944 | 1.51 | — | — | \$ 178,630 | — | — |
| Taiflex Scientific Co., Ltd. | Shenzhen Taiflex Electronic Co., Ltd. | Holds 100% of the third-tier subsidiary | 211,419 | (Note 1) | — | — | 32,428 | — | — |

Note 1: Those receivables from related parties are recognized as other receivables; thus, turnover ratio analysis does not apply.

TABLE 6: INVESTEEES OVER WHICH THE COMPANY EXERCISES SIGNIFICANT INFLUENCE OR CONTROL DIRECTLY OR INDIRECTLY (EXCLUDING INVESTEEES IN MAINLAND CHINA)
(In Thousands of New Taiwan Dollars)

| Investor | Investee | Business Location | Main Businesses and Products | Original Investment Amount | | Balance as of December 31, 2018 | | | Net Income (Loss) of Investee | Share of Profit/Loss | Note |
|--------------------------------|------------------------------------|-------------------|--|----------------------------|-------------------|---------------------------------|-------------------------|----------------|-------------------------------|----------------------|----------|
| | | | | December 31, 2018 | December 31, 2017 | Shares (In Thousands) | Shareholding Percentage | Carrying Value | | | |
| Taiflex Scientific Co., Ltd. | Taistar Co., Ltd. | Belize | Investment holding | \$ 704,536 | \$ 822,194 | 21,825 | 100.00% | \$ 1,133,837 | \$ (314,924) | \$ (313,497) | (Note 1) |
| Taiflex Scientific Co., Ltd. | Leadmax Limited | Samoa | Trading of electronic materials | 337 | 337 | 10 | 100.00% | 10,990 | (5,114) | (5,114) | — |
| Taiflex Scientific Co., Ltd. | Koatech Technology Corporation | Taiwan | Manufacturing and selling of electronic materials and components | 294,102 | 294,102 | 13,700 | 53.86% | 233,440 | 15,053 | 2,669 | (Note 2) |
| Taiflex Scientific Co., Ltd. | Innovision FlexTech Corp. | Taiwan | Manufacturing and selling of electronic materials | 102,894 | 102,894 | 3,611 | 15.07% | 51,470 | 72,099 | 19,666 | — |
| Taiflex Scientific Co., Ltd. | TFS Co., Ltd. | Belize | Investment holding | 478,797 | 478,797 | 15,520 | 100.00% | 469,677 | 50,426 | 50,426 | — |
| Taiflex Scientific Co., Ltd. | Richstar Co., Ltd. | Samoa | Investment holding | 525,733 | — | 17,500 | 53.01% | 564,429 | 60,903 | 10,408 | — |
| Taiflex Scientific Co., Ltd. | Taiflex Scientific Japan Co., Ltd. | Japan | Trading and technical support of electronic materials | 16,260 | 16,260 | 6 | 100.00% | 17,696 | 331 | 331 | — |
| Taiflex Scientific Co., Ltd. | Taiflex USA Corporation | U.S.A. | Technical support and marketing of electronic materials | 8,820 | — | 1 | 100.00% | 8,861 | (348) | (348) | — |
| TFS Co., Ltd. | Richstar Co., Ltd. | Samoa | Investment holding | 478,563 | 478,563 | 15,510 | 46.99% | 500,245 | 60,903 | 50,495 | — |
| Taistar Co., Ltd. | TSC International Ltd. | Cayman Islands | Investment holding | 683,946 | 801,604 | 21,170 | 100.00% | 1,111,768 | (295,253) | (295,253) | — |
| Koatech Technology Corporation | KTC Global Co., Ltd. | Samoa | Investment holding | 28,649 | 28,649 | 960 | 100.00% | 14,776 | (1,584) | (1,584) | — |
| KTC Global Co., Ltd | KTC PanAsia Co., Ltd. | Samoa | Investment holding | 28,500 | 28,500 | 955 | 100.00% | 15,369 | (2,127) | (2,127) | — |

Note 1: Including unrealized gain/loss between affiliates.

Note 2: Including amortization of property, plant and equipment.

TABLE 7: INFORMATION ON INVESTMENTS IN MAINLAND CHINA

(In Thousands of New Taiwan Dollars)

| Investee | Main Businesses and Products | Total Amount of Paid-in Capital | Method of Investment (Note 1) | Accumulated Outflow of Investment from Taiwan as of January 1, 2018 | Investment Flows | | Accumulated Outflow of Investment from Taiwan as of December 31, 2018 | Profit/Loss of Investee | Percentage of Ownership (Direct or Indirect Investment) | Share of Profit/Loss | Carrying Amount as of December 31, 2018 | Accumulated Inward Remittance of Earnings as of December 31, 2018 |
|---|--|---------------------------------|-------------------------------|---|------------------|-----------|---|---------------------------|---|----------------------|---|---|
| | | | | | Outflow | Inflow | | | | | | |
| Kunshan Taiflex Electronic Material Co., Ltd. | Trading of coating materials for high polymer film and copper foil | — (Note 3) | 2 | \$ 32,536 | — | \$ 32,536 | — | — | — | \$ 1,294 | — | \$ 196,579 |
| Taiflex Scientific (Kunshan) Co., Ltd. | Manufacturing and selling of coating materials for high polymer film and copper foil | \$767,141 (US\$24,000,000) | 2 | 767,141 | — | — | \$ 767,141 | \$(332,082) | 100.00% | (332,082) | \$ 1,111,666 | — |
| Kunshan Koatech Technology Corporation | A wholesaler and a commission agent of electronic materials and components | \$28,351 (US\$950,000) | 2 | 28,351 | — | — | 28,351 | (2,127) | 53.86% | (1,145) | 8,270 | — |
| Shenzhen Taiflex Electronic Co., Ltd. | Trading of coating materials for high polymer film and copper foil | \$479,160 (US\$15,500,000) | 2 | 479,160 | — | — | 479,160 | 49,564 | 100.00% | 49,564 | 542,127 | — |
| Rudong Fuzhan Scientific Co., Ltd. | Manufacturing and selling of electronic materials | \$525,733 (US\$17,500,000) | 2 | — | \$525,733 | — | 525,733 | 11,405 | 100.00% | 11,405 | 522,412 | — |
| Accumulated Outflow of Investment from Taiwan to Mainland China as of December 31, 2018 | | | | Investment Amounts Authorized by the Investment Commission, MOEA | | | | Upper Limit on Investment | | | | |
| \$1,800,385 | | | | \$2,367,190 | | | | \$4,357,343 | | | | |

Note 1: The methods for investment in Mainland China are categorized into the following three types. Please specify the type.

- (1) Direct investment in Mainland China.
- (2) Investment in Mainland China through companies in the third area.
- (3) Others.

Note 2: Significant transactions with the investees in China directly or indirectly through the third area and the relevant prices, payment terms and unrealized gains and losses:

- (1) Purchase and ending balance of related payables and their weightings: see Table 4.
- (2) Sales and ending balance of related receivables and their weightings: see Tables 4 and 5.
- (3) The transaction amount and gain or loss arising from property transactions: N/A.
- (4) Ending balance of endorsements/guarantees or collateral provided and the purposes: see Table 2.
- (5) Maximum balance, ending balance, interest rate range and total interest of current period from financing provided to others: see Table 1.
- (6) Transactions that have significant impact on profit or loss of the current period or the financial position, such as services rendered or received: N/A.

Note 3: The liquidation of Kunshan Taiflex Electronic Material Co., Ltd. was completed by August, 2018.

TABLE 8: INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS FOR THE YEAR ENDED DECEMBER 31, 2018
(In Thousands of New Taiwan Dollars)

| No. (Note 1) | Company Name | Counterparty | Relationship (Note 2) | Intercompany Transactions | | | |
|-----------------|------------------------------|--|--------------------------|---------------------------------|--------------------|-----------------------|--|
| | | | | Financial Statements Account | Amount (Note 4) | Terms | Percentage to Consolidated Net Revenue or Total Assets (Note 3) |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | 1 | Sales revenue | \$ 96,405 | General trading terms | 1.00% |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | 1 | Accounts receivable | 29,140 | General trading terms | 0.24% |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | 1 | Other receivables | 13,747 | — | 0.12% |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | 1 | Other receivables | 721,744 | Financing | 6.04% |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | 1 | Cost of revenue | 109,900 | General trading terms | 1.14% |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | 1 | Accounts payable | 24,716 | General trading terms | 0.21% |
| 0 | Taiflex Scientific Co., Ltd. | Taiflex Scientific (Kunshan) Co., Ltd. | 1 | Purchase on behalf of others | 20,425 | — | 0.21% |
| 0 | Taiflex Scientific Co., Ltd. | Shenzhen Taiflex Electronic Co., Ltd. | 1 | Sales revenue | 2,096,373 | General trading terms | 21.74% |
| 0 | Taiflex Scientific Co., Ltd. | Shenzhen Taiflex Electronic Co., Ltd. | 1 | Accounts receivable | 1,318,944 | General trading terms | 11.04% |
| 0 | Taiflex Scientific Co., Ltd. | Shenzhen Taiflex Electronic Co., Ltd. | 1 | Other receivables | 211,419 | — | 1.77% |
| 0 | Taiflex Scientific Co., Ltd. | Shenzhen Taiflex Electronic Co., Ltd. | 1 | Other receivables | 276,498 | Financing | 2.32% |

Note 1: Transaction information between the parent company and its subsidiaries shall be disclosed by codes below:

- (1) Taiflex Scientific Co., Ltd. is coded "0".
- (2) The subsidiaries are coded from "1" in the order presented in the table above.

Note 2: Relationships are categorized into the following three types. Please specify the type.

- (1) From the parent company to a subsidiary.
- (2) From a subsidiary to the parent company.
- (3) Between subsidiaries.

Note 3: Regarding the percentage of transaction amount to consolidated net revenue or total assets, it is computed based on the ending balance to the consolidated total assets for balance sheet items; and based on the interim accumulated amount to the consolidated net revenue for profit or loss items.

Note 4: This is the ending balance after evaluation.